{"text_format":"3","workbook":"xlsx","n_sheets":64,"sheets":["Document and Entity Information","Consolidated Balance Sheets","Consolidated Balance Sheets (Pa","Consolidated Statements of Oper","Consolidated Statements of Comp","Consolidated Statements of Stoc","Consolidated Statements of St_2","Consolidated Statements of Cash","Consolidated Statements of Ca_2","Cybersecurity Risk Management, ","Pay vs Performance Disclosure","Insider Trading Arrangements","Nature of the Business and Basi","Summary of Significant Accounti","Fair Value Measurement","Prepaid Expenses and Other Curr","Other Assets and Long-Term Depo","Other Current Liabilities","Common Stock","Stock-Based Compensation","Income Taxes","Net Loss Per Common Share","Lease","Commitments and Contingencies","Summary of Significant Accoun_2","Fair Value Measurement (Tables)","Prepaid Expenses and Other Cu_2","Other Assets and Long-Term De_2","Other Current Liabilities (Tabl","Common Stock (Tables)","Stock-Based Compensation (Table","Income Taxes (Tables)","Net Loss Per Common Share (Tabl","Lease (Tables)","Nature of the Business and Ba_2","Summary of Significant Accoun_3","Fair Value Measurement - Schedu","Fair Value Measurement - Sche_2","Fair Value Measurement - Additi","Property and Equipment, Net - S","Prepaid Expenses and Other Cu_3","Other Assets and Long-Term De_3","Other Current Liabilities - Sch","Common Stock - Schedule of Comm","Common Stock (Additional Inform","Stock-Based Compensation - Addi","Stock-Based Compensation - Sche","Stock-Based Compensation - Sc_2","Stock-Based Compensation - Summ","Stock Based Compensation - Perf","Stock-Based Compensation - 2020","Stock-Based Compensation - Sc_3","Income Taxes - Schedule of Reco","Income Taxes - Schedule of Defe","Income Taxes - Additional Infor","Income Taxes - Schedule of Valu","Net Loss Per Common Share - Sch","Net Loss Per Common Share - S_2","Lease - Additional Information ","Lease - Summary of Total Lease ","Lease - Summary of Supplemental","Lease - Summary of Future Minim","Lease - Summary of Lease Term a","Commitments and Contingencies -"],"cells_cut":2,"read":"whole","date_system":"1900"}

{"sheet":"Document and Entity Information","index":0,"n_rows":42,"n_cols":4,"rows_kept":42,"merged":[[0,0,1,0]]}
["Document and Entity Information - USD ($) $ in Millions","12 Months Ended"]
[null,"Dec. 31, 2024","Mar. 13, 2025","Jun. 28, 2024"]
["Cover [Abstract]"," "," "," "]
["Document Type","10-K"," "," "]
["Document Annual Report","true"," "," "]
["Document Transition Report","false"," "," "]
["Document Period End Date","Dec. 31,  2024"," "," "]
["Entity File Number","001-39712"," "," "]
["Entity Registrant Name","OLEMA PHARMACEUTICALS, INC."," "," "]
["Entity Incorporation, State or Country Code","DE"," "," "]
["Entity Tax Identification Number","30-0409740"," "," "]
["Entity Address, Address Line One","780 Brannan Street"," "," "]
["Entity Address, City or Town","San Francisco"," "," "]
["Entity Address, State or Province","CA"," "," "]
["Entity Address, Postal Zip Code","94103"," "," "]
["City Area Code","415"," "," "]
["Local Phone Number","651-3316"," "," "]
["Title of 12(b) Security","Common Stock"," "," "]
["Trading Symbol","OLMA"," "," "]
["Security Exchange Name","NASDAQ"," "," "]
["Entity Well-known Seasoned Issuer","No"," "," "]
["Entity Voluntary Filers","No"," "," "]
["Entity Current Reporting Status","Yes"," "," "]
["Entity Interactive Data Current","Yes"," "," "]
["Entity Filer Category","Non-accelerated Filer"," "," "]
["Entity Small Business","true"," "," "]
["Entity Emerging Growth Company","false"," "," "]
["Entity Shell Company","false"," "," "]
["Entity Public Float"," "," ",{"v":454.3,"d":"$ 454.3"}]
["ICFR Auditor Attestation Flag","false"," "," "]
["Document Financial Statement Error Correction [Flag]","false"," "," "]
["Entity Common Stock, Shares Outstanding"," ",{"v":68333065,"d":"68,333,065 "}," "]
["Auditor Name","Ernst & Young LLP"," "," "]
["Auditor Firm ID","42"," "," "]
["Auditor Location","Iselin, New Jersey"," "," "]
["Entity Central Index Key","0001750284"," "," "]
["Current Fiscal Year End Date","--12-31"," "," "]
["Document Fiscal Year Focus","2024"," "," "]
["Document Fiscal Period Focus","FY"," "," "]
["Amendment Flag","false"," "," "]
["Documents Incorporated by Reference [Text Block]","DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s definitive Proxy Statement for the 2024 Annual Meeting of Stockholders to be filed with the U.S. Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10‑K are incorporated by reference in Part III, Items 10‑14 of this Annual Report on Form 10‑K."," "," "]
["Opinion on the Financial Statements","Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Olema Pharmaceuticals, Inc. (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, stockholders' equity, and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles."," "," "]

{"sheet":"Consolidated Balance Sheets","index":1,"n_rows":25,"n_cols":3,"rows_kept":25}
["Consolidated Balance Sheets - USD ($) $ in Thousands","Dec. 31, 2024","Dec. 31, 2023"]
["Current assets:"," "," "]
["Cash and cash equivalents",{"v":139480,"d":"$ 139,480"},{"v":68539,"d":"$ 68,539"}]
["Marketable securities",{"v":294606,"d":"294,606 "},{"v":193268,"d":"193,268 "}]
["Prepaid expenses and other current assets",{"v":4387,"d":"4,387 "},{"v":4706,"d":"4,706 "}]
["Total current assets",{"v":438473,"d":"438,473 "},{"v":266513,"d":"266,513 "}]
["Operating lease right-of-use assets",{"v":1314,"d":"1,314 "},{"v":2291,"d":"2,291 "}]
["Other assets and long-term deposits",{"v":11192,"d":"11,192 "},{"v":8141,"d":"8,141 "}]
["Total assets",{"v":450979,"d":"450,979 "},{"v":276945,"d":"276,945 "}]
["Current liabilities:"," "," "]
["Accounts payable",{"v":4460,"d":"4,460 "},{"v":2698,"d":"2,698 "}]
["Operating lease liabilities, current",{"v":1172,"d":"1,172 "},{"v":988,"d":"988 "}]
["Other current liabilities",{"v":36126,"d":"36,126 "},{"v":17935,"d":"17,935 "}]
["Total current liabilities",{"v":41758,"d":"41,758 "},{"v":21621,"d":"21,621 "}]
["Operating lease liabilities, net of current portion",{"v":257,"d":"257 "},{"v":1429,"d":"1,429 "}]
["Total liabilities",{"v":42015,"d":"42,015 "},{"v":23050,"d":"23,050 "}]
["Commitments and contingencies (Note 12)"," "," "]
["Stockholders' equity:"," "," "]
["Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2024 and December 31, 2023; no shares issued and outstanding as of December 31, 2024 and December 31, 2023."," "," "]
["Common stock, $0.0001 par value; 490,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 74,312,608 and 55,097,118 shares issued as of December 31, 2024 and December 31, 2023, respectively; 74,312,608 and 54,992,784 shares outstanding as of December 31, 2024 and December 31, 2023, respectively.",{"v":6,"d":"6 "},{"v":4,"d":"4 "}]
["Additional paid-in capital",{"v":843921,"d":"843,921 "},{"v":559176,"d":"559,176 "}]
["Accumulated other comprehensive income",{"v":143,"d":"143 "},{"v":347,"d":"347 "}]
["Accumulated deficit",{"v":-435106,"d":"(435,106)"},{"v":-305632,"d":"(305,632)"}]
["Total stockholders' equity",{"v":408964,"d":"408,964 "},{"v":253895,"d":"253,895 "}]
["Total liabilities and stockholders' equity",{"v":450979,"d":"$ 450,979"},{"v":276945,"d":"$ 276,945"}]

{"sheet":"Consolidated Balance Sheets (Pa","index":2,"n_rows":10,"n_cols":3,"rows_kept":10}
["Consolidated Balance Sheets (Parenthetical) - $ / shares","Dec. 31, 2024","Dec. 31, 2023"]
["Statement of Financial Position [Abstract]"," "," "]
["Preferred stock, par value (in dollars per share)",{"v":0.0001,"d":"$ 0.0001"},{"v":0.0001,"d":"$ 0.0001"}]
["Preferred stock, authorized (in shares)",{"v":10000000,"d":"10,000,000 "},{"v":10000000,"d":"10,000,000 "}]
["Preferred stock, issued (in shares)",{"v":0,"d":"0 "},{"v":0,"d":"0 "}]
["Preferred stock, outstanding (in shares)",{"v":0,"d":"0 "},{"v":0,"d":"0 "}]
["Common stock, par value (in dollars per share)",{"v":0.0001,"d":"$ 0.0001"},{"v":0.0001,"d":"$ 0.0001"}]
["Common stock, authorized (in shares)",{"v":490000000,"d":"490,000,000 "},{"v":490000000,"d":"490,000,000 "}]
["Common stock, issued (in shares)",{"v":74312608,"d":"74,312,608 "},{"v":55097118,"d":"55,097,118 "}]
["Common stock, outstanding (in shares)",{"v":74312608,"d":"74,312,608 "},{"v":54992784,"d":"54,992,784 "}]

{"sheet":"Consolidated Statements of Oper","index":3,"n_rows":16,"n_cols":3,"rows_kept":16,"merged":[[0,0,1,0],[0,1,0,2]]}
["Consolidated Statements of Operations - USD ($) $ in Thousands","12 Months Ended"]
[null,"Dec. 31, 2024","Dec. 31, 2023"]
["Operating expenses:"," "," "]
["Research and development",{"v":124517,"d":"$ 124,517"},{"v":86140,"d":"$ 86,140"}]
["General and administrative",{"v":17741,"d":"17,741 "},{"v":18821,"d":"18,821 "}]
["Total operating expenses",{"v":142258,"d":"142,258 "},{"v":104961,"d":"104,961 "}]
["Loss from operations",{"v":-142258,"d":"(142,258)"},{"v":-104961,"d":"(104,961)"}]
["Other income (expense):"," "," "]
["Interest income",{"v":12682,"d":"12,682 "},{"v":8325,"d":"8,325 "}]
["Other income (expense):",{"v":102,"d":"102 "},{"v":-19,"d":"(19)"}]
["Total other income",{"v":12784,"d":"12,784 "},{"v":8306,"d":"8,306 "}]
["Net loss",{"v":-129474,"d":"$ (129,474)"},{"v":-96655,"d":"$ (96,655)"}]
["Net loss per share, basic (in dollars per share)",{"v":-2.2,"d":"$ (2.2)"},{"v":-2.14,"d":"$ (2.14)"}]
["Net loss per share, diluted (in dollars per share)",{"v":-2.2,"d":"$ (2.2)"},{"v":-2.14,"d":"$ (2.14)"}]
["Weighted average shares used to compute net loss per share, basic (in shares)",{"v":58743522,"d":"58,743,522 "},{"v":45247098,"d":"45,247,098 "}]
["Weighted average shares used to compute net loss per share, diluted (in shares)",{"v":58743522,"d":"58,743,522 "},{"v":45247098,"d":"45,247,098 "}]

{"sheet":"Consolidated Statements of Comp","index":4,"n_rows":7,"n_cols":3,"rows_kept":7,"merged":[[0,0,1,0],[0,1,0,2]]}
["Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands","12 Months Ended"]
[null,"Dec. 31, 2024","Dec. 31, 2023"]
["Statement of Comprehensive Income [Abstract]"," "," "]
["Net loss",{"v":-129474,"d":"$ (129,474)"},{"v":-96655,"d":"$ (96,655)"}]
["Other comprehensive loss:"," "," "]
["Net unrealized gain (loss) on marketable securities",{"v":-204,"d":"(204)"},{"v":2160,"d":"2,160 "}]
["Total comprehensive loss",{"v":-129678,"d":"$ (129,678)"},{"v":-94495,"d":"$ (94,495)"}]

{"sheet":"Consolidated Statements of Stoc","index":5,"n_rows":39,"n_cols":6,"rows_kept":39}
["Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands","Total","Common Stock","Additional Paid-in Capital","Accumulated Other Comprehensive (Loss) Gain","Accumulated Deficit"]
["Balances, at Beginning of period at Dec. 31, 2022",{"v":197546,"d":"$ 197,546"},{"v":3,"d":"$ 3"},{"v":408333,"d":"$ 408,333"},{"v":-1813,"d":"$ (1,813)"},{"v":-208977,"d":"$ (208,977)"}]
["Balances, at Beginning of period (in shares) at Dec. 31, 2022"," ",{"v":40287097,"d":"40,287,097 "}," "," "," "]
["Increase (Decrease) in Stockholders' Equity [Roll Forward]"," "," "," "," "," "]
["Issuance of shares under equity private placement, net of issuance costs of $264",{"v":129736,"d":"129,736 "},{"v":1,"d":"$ 1"},{"v":129735,"d":"129,735 "}," "," "]
["Issuance of shares under equity private placement, net of issuance costs of $264 (in shares)"," ",{"v":13211381,"d":"13,211,381 "}," "," "," "]
["Stock-based compensation expense",{"v":16804,"d":"16,804 "}," ",{"v":16804,"d":"16,804 "}," "," "]
["Employee stock purchase plan expense",{"v":452,"d":"452 "}," ",{"v":452,"d":"452 "}," "," "]
["Exercise of stock options",{"v":2722,"d":"2,722 "}," ",{"v":2722,"d":"2,722 "}," "," "]
["Exercise of stock options (in shares)"," ",{"v":733867,"d":"733,867 "}," "," "," "]
["Issuance of shares under employee stock purchase plan",{"v":1050,"d":"1,050 "}," ",{"v":1050,"d":"1,050 "}," "," "]
["Issuance of shares under employee stock purchase plan (in shares)"," ",{"v":333503,"d":"333,503 "}," "," "," "]
["Vesting of early exercised stock options",{"v":80,"d":"$ 80"}," ",{"v":80,"d":"80 "}," "," "]
["Vesting of early exercised stock options (in shares)",{"v":2329483,"d":"2,329,483 "},{"v":18640,"d":"18,640 "}," "," "," "]
["Vesting of restricted stock awards (in shares)"," ",{"v":191296,"d":"191,296 "}," "," "," "]
["Vesting of performance-based restricted stock unit awards (in shares)"," ",{"v":217000,"d":"217,000 "}," "," "," "]
["Net unrealized gain (loss) on marketable securities",{"v":2160,"d":"$ 2,160"}," "," ",{"v":2160,"d":"2,160 "}," "]
["Net Income (Loss)",{"v":-96655,"d":"(96,655)"}," "," "," ",{"v":-96655,"d":"(96,655)"}]
["Balances, at End of period at Dec. 31, 2023",{"v":253895,"d":"253,895 "},{"v":4,"d":"$ 4"},{"v":559176,"d":"559,176 "},{"v":347,"d":"347 "},{"v":-305632,"d":"(305,632)"}]
["Balances, at End of period (in shares) at Dec. 31, 2023"," ",{"v":54992784,"d":"54,992,784 "}," "," "," "]
["Increase (Decrease) in Stockholders' Equity [Roll Forward]"," "," "," "," "," "]
["Stock-based compensation expense",{"v":22009,"d":"22,009 "}," ",{"v":22009,"d":"22,009 "}," "," "]
["Employee stock purchase plan expense",{"v":573,"d":"573 "}," ",{"v":573,"d":"573 "}," "," "]
["Issuance of shares and pre-funded warrants under equity private placement, net of issuance costs of $12,998",{"v":237001,"d":"237,001 "},{"v":2,"d":"$ 2"},{"v":236999,"d":"236,999 "}," "," "]
["Issuance of shares and pre-funded warrants under equity private placement, net of issuance costs of $12,998 (in shares)"," ",{"v":19928875,"d":"19,928,875 "}," "," "," "]
["Issuance of shares under at-the-market offering, net of issuance costs of $166",{"v":22787,"d":"22,787 "}," ",{"v":22787,"d":"22,787 "}," "," "]
["Issuance of shares under at-the-market offering, net of issuance costs of $166 (in shares)"," ",{"v":1772278,"d":"1,772,278 "}," "," "," "]
["Exchange of common stock shares for pre-funded warrants (in shares)"," ",{"v":-3420000,"d":"(3,420,000)"}," "," "," "]
["Exercise of stock options",{"v":1518,"d":"$ 1,518"}," ",{"v":1518,"d":"1,518 "}," "," "]
["Exercise of stock options (in shares)",{"v":460744,"d":"460,744 "},{"v":430159,"d":"430,159 "}," "," "," "]
["Issuance of shares under employee stock purchase plan",{"v":859,"d":"$ 859"}," ",{"v":859,"d":"859 "}," "," "]
["Issuance of shares under employee stock purchase plan (in shares)"," ",{"v":112853,"d":"112,853 "}," "," "," "]
["Vesting of early exercised stock options (in shares)",{"v":2213715,"d":"2,213,715 "}," "," "," "," "]
["Vesting of restricted stock awards (in shares)"," ",{"v":92659,"d":"92,659 "}," "," "," "]
["Vesting of performance-based restricted stock unit awards (in shares)"," ",{"v":403000,"d":"403,000 "}," "," "," "]
["Net unrealized gain (loss) on marketable securities",{"v":-204,"d":"$ (204)"}," "," ",{"v":-204,"d":"(204)"}," "]
["Net Income (Loss)",{"v":-129474,"d":"(129,474)"}," "," "," ",{"v":-129474,"d":"(129,474)"}]
["Balances, at End of period at Dec. 31, 2024",{"v":408964,"d":"$ 408,964"},{"v":6,"d":"$ 6"},{"v":843921,"d":"$ 843,921"},{"v":143,"d":"$ 143"},{"v":-435106,"d":"$ (435,106)"}]
["Balances, at End of period (in shares) at Dec. 31, 2024"," ",{"v":74312608,"d":"74,312,608 "}," "," "," "]

{"sheet":"Consolidated Statements of St_2","index":6,"n_rows":7,"n_cols":5,"rows_kept":7,"merged":[[0,0,1,0],[0,3,0,4]]}
["Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($) $ in Thousands",null,null,"12 Months Ended"]
[null,"Nov. 29, 2024","Sep. 05, 2023","Dec. 31, 2024","Dec. 31, 2023"]
["Net of issuance costs"," "," "," ",{"v":264,"d":"$ 264"}]
["Private Placement [Member]"," "," "," "," "]
["Net of issuance costs",{"v":6500,"d":"$ 6,500"},{"v":300,"d":"$ 300"},{"v":12998,"d":"$ 12,998"}," "]
["At The Market Offering [Member]"," "," "," "," "]
["Net of issuance costs"," "," ",{"v":166,"d":"$ 166"}," "]

{"sheet":"Consolidated Statements of Cash","index":7,"n_rows":37,"n_cols":3,"rows_kept":37,"merged":[[0,0,1,0],[0,1,0,2]]}
["Consolidated Statements of Cash Flows - USD ($) $ in Thousands","12 Months Ended"]
[null,"Dec. 31, 2024","Dec. 31, 2023"]
["Cash flows from operating activities:"," "," "]
["Net loss",{"v":-129474,"d":"$ (129,474)"},{"v":-96655,"d":"$ (96,655)"}]
["Adjustments to reconcile net loss to net cash used in operating activities:"," "," "]
["Depreciation and amortization expense",{"v":393,"d":"393 "},{"v":377,"d":"377 "}]
["Loss on disposal of equipment",{"v":9,"d":"9 "},{"v":111,"d":"111 "}]
["Non-cash lease expense",{"v":1150,"d":"1,150 "},{"v":1297,"d":"1,297 "}]
["Non-cash interest income on marketable securities",{"v":-8175,"d":"(8,175)"},{"v":-5524,"d":"(5,524)"}]
["Stock-based compensation expense, including employee stock purchase plan expense",{"v":22582,"d":"22,582 "},{"v":17256,"d":"17,256 "}]
["Changes in operating assets and liabilities:"," "," "]
["Prepaid expenses and other current assets",{"v":-429,"d":"(429)"},{"v":694,"d":"694 "}]
["Other assets and long-term deposits",{"v":-2957,"d":"(2,957)"},{"v":-5324,"d":"(5,324)"}]
["Accounts payable",{"v":2510,"d":"2,510 "},{"v":2324,"d":"2,324 "}]
["Other current liabilities",{"v":11202,"d":"11,202 "},{"v":2948,"d":"2,948 "}]
["Operating lease liabilities",{"v":-1162,"d":"(1,162)"},{"v":-1231,"d":"(1,231)"}]
["Net cash used in operating activities",{"v":-104351,"d":"(104,351)"},{"v":-83727,"d":"(83,727)"}]
["Cash flows from investing activities:"," "," "]
["Maturities of marketable securities",{"v":301592,"d":"301,592 "},{"v":250760,"d":"250,760 "}]
["Purchases of marketable securities",{"v":-394959,"d":"(394,959)"},{"v":-255625,"d":"(255,625)"}]
["Purchase of equipment",{"v":-159,"d":"(159)"}," "]
["Disposal of fixed assets"," ",{"v":14,"d":"14 "}]
["Net cash used in investing activities",{"v":-93526,"d":"(93,526)"},{"v":-4851,"d":"(4,851)"}]
["Cash flows from financing activities:"," "," "]
["Proceeds from equity private placement, net of issuance costs of $6,498",{"v":243501,"d":"243,501 "},{"v":129736,"d":"129,736 "}]
["Proceeds from at-the-market offering, net of issuance costs of $166",{"v":22787,"d":"22,787 "}," "]
["Proceeds from exercise of stock options",{"v":1671,"d":"1,671 "},{"v":2629,"d":"2,629 "}]
["Proceeds from issuance of common stock under the ESPP plan",{"v":859,"d":"859 "},{"v":1050,"d":"1,050 "}]
["Net cash provided by financing activities",{"v":268818,"d":"268,818 "},{"v":133415,"d":"133,415 "}]
["Net increase in cash and cash equivalents",{"v":70941,"d":"70,941 "},{"v":44837,"d":"44,837 "}]
["Cash and cash equivalents at beginning of period",{"v":68539,"d":"68,539 "},{"v":23702,"d":"23,702 "}]
["Cash and cash equivalents at end of period",{"v":139480,"d":"139,480 "},{"v":68539,"d":"$ 68,539"}]
["Supplemental disclosure of non-cash investing and financing activities:"," "," "]
["Issuance costs for equity private placement not paid in cash by the end of period",{"v":6500,"d":"6,500 "}," "]
["Exchange common stock shares for pre-funded warrants",{"v":31054,"d":"31,054 "}," "]
["Research and development project deposit applied against final study invoices",{"v":748,"d":"748 "}," "]
["System implementation cost included in other current liabilities",{"v":-337,"d":"$ (337)"}," "]

{"sheet":"Consolidated Statements of Ca_2","index":8,"n_rows":6,"n_cols":2,"rows_kept":6,"merged":[[0,0,1,0]]}
["Consolidated Statements of Cash Flows (Parenthetical) $ in Thousands","12 Months Ended"]
[null,"Dec. 31, 2024 USD ($)"]
["Equity Private Placement"," "]
["Net of issuance costs",{"v":6498,"d":"$ 6,498"}]
["At-The-Market Offering"," "]
["Net of issuance costs",{"v":166,"d":"$ 166"}]

{"sheet":"Cybersecurity Risk Management, ","index":9,"n_rows":19,"n_cols":2,"rows_kept":19,"merged":[[0,0,1,0]]}
["Cybersecurity Risk Management, Strategy, and Governance","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Cybersecurity Risk Management, Strategy, and Governance [Line Items]"," "]
["Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]","Item 1C. Cybersecurity. Risk management and strategy We have established and maintain various information security processes designed to identify, assess, and manage cybersecurity risks to our critical computer networks, third-party hosted services, communication systems, hardware, software, and vital data, such as intellectual property, confidential proprietary information, strategic assets, and non-clinical/clinical trial data (Information Systems and Data). Our Chief Operating and Financial Officer, Vice President of Information Technology, vCISO (Virtual Chief Information Security Officer), cybersecurity business partner and IT & Legal teams collaborate to address cybersecurity threats and risks, leveraging our risk register when needed. Our VP of Information Technology, vCISO, members of our in-house IT team, and our third-party cybersecurity business partner all play an active role in monitoring and assessing risks from cyber threats through a variety of methods including automated tools, third-party testing, tabletop incident response exercises, threat actor analysis, industry risk profiling, and collaboration with law enforcement. We employ a range of measures, processes, standards, and policies tailored to specific environments designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data. These include data encryption, network security controls, secure physical facilities, employee training, access management, change management and comprehensive asset management, tracking, and disposal procedures. Our assessment and management of material risks from cybersecurity threats are integrated into the Company’s overall risk management processes. For example, the security team, which includes our VP of Information Technology, vCISO, and third-party service providers, works with management to prioritize our risk management processes and take steps to mitigate cybersecurity threats that are determined to be more likely to lead to a material impact to our business. Key findings and status of the cybersecurity landscape are reviewed with the Audit Committee of our Board of Directors (the Audit Committee), which evaluates our overall enterprise risk. We engage various categories of third-party service providers to augment our efforts in monitoring, identifying, assessing, and mitigating significant cybersecurity risks. These third-party service providers encompass a range of expertise, including professional services firms such as legal counsel, cybersecurity consultants with specialized knowledge, providers of cybersecurity software solutions, managed cybersecurity service providers offering ongoing monitoring, protection and support, external testing firms specializing items like penetration testing to evaluate vulnerabilities, and forensic investigators who are enlisted as necessary to conduct comprehensive investigations and assessments when specific incidents or breaches occur. We enlist third-party service providers across our business functions, including application providers, hosting companies, contract manufacturers, and supply chain resources. Depending on the service type, data sensitivity, and provider identity, our vendor management process assesses cybersecurity risks and establishes corresponding contractual cybersecurity obligations, tailored to each provider's role and the nature of Information Systems and Data involved. For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see our risk factors under \"Part 1. Item 1A. Risk Factors\" in this Annual Report on Form 10-K, including under the section titled \" — Risks related to employee matters, managing our growth and other risks related to our business.\" Governance Our Board of Directors retains responsibility for evaluating key business risks faced by the Company, including but not limited to information security. In part, our Board of Directors addresses its general oversight function by delegating the Company's cybersecurity risk management to the Audit Committee. The Audit Committee's responsibilities include supervising risk mitigation efforts related to cybersecurity threats, evaluating the sufficiency and effectiveness of information security policies and practices, and ensuring robust internal controls for information security. Our cybersecurity risk assessment and management processes are implemented and maintained by certain members of Company management, including our Vice President of Information Technology who has over 15 years of extensive experience managing cybersecurity programs, who reports into our Chief Operating and Financial Officer. The Vice President of Information Technology is responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company's overall risk management strategy, and communicating key priorities to relevant personnel. The Chief Operating and Financial Officer is responsible for approving budgets, aiding in the preparation for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports. Our cybersecurity incident response procedures involve escalating specific incidents to certain members of management as needed, including the Vice President of Information Technology, Chief Operating and Financial Officer and the Chief Executive Officer. The Chief Operating and Financial Officer collaborates with our incident response team, which includes members of our in-house IT, facilities, human resources, regulatory, legal, and communications teams, to address and resolve reported cybersecurity incidents. Olema’s incident response procedures mandate reporting certain types of cybersecurity incidents to the Audit Committee and other agencies as required by law. The Audit Committee periodically receives reports from the Vice President of Information Technology on the Company's significant cybersecurity threats, risks, and mitigation processes. The Audit Committee also receives various summaries, presentations, and reports pertaining to cybersecurity threats, risks, and mitigation."]
["Cybersecurity Risk Management Processes Integrated [Flag]","true"]
["Cybersecurity Risk Management Processes Integrated [Text Block]","Our assessment and management of material risks from cybersecurity threats are integrated into the Company’s overall risk management processes. For example, the security team, which includes our VP of Information Technology, vCISO, and third-party service providers, works with management to prioritize our risk management processes and take steps to mitigate cybersecurity threats that are determined to be more likely to lead to a material impact to our business. Key findings and status of the cybersecurity landscape are reviewed with the Audit Committee of our Board of Directors (the Audit Committee), which evaluates our overall enterprise risk."]
["Cybersecurity Risk Management Third Party Engaged [Flag]","true"]
["Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]","true"]
["Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]","true"]
["Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]","For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see our risk factors under \"Part 1. Item 1A. Risk Factors\" in this Annual Report on Form 10-K, including under the section titled \" — Risks related to employee matters, managing our growth and other risks related to our business.\" "]
["Cybersecurity Risk Board of Directors Oversight [Text Block]","Our Board of Directors retains responsibility for evaluating key business risks faced by the Company, including but not limited to information security. In part, our Board of Directors addresses its general oversight function by delegating the Company's cybersecurity risk management to the Audit Committee. The Audit Committee's responsibilities include supervising risk mitigation efforts related to cybersecurity threats, evaluating the sufficiency and effectiveness of information security policies and practices, and ensuring robust internal controls for information security."]
["Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]","In part, our Board of Directors addresses its general oversight function by delegating the Company's cybersecurity risk management to the Audit Committee. The Audit Committee's responsibilities include supervising risk mitigation efforts related to cybersecurity threats, evaluating the sufficiency and effectiveness of information security policies and practices, and ensuring robust internal controls for information security."]
["Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]","The Audit Committee periodically receives reports from the Vice President of Information Technology on the Company's significant cybersecurity threats, risks, and mitigation processes. The Audit Committee also receives various summaries, presentations, and reports pertaining to cybersecurity threats, risks, and mitigation."]
["Cybersecurity Risk Role of Management [Text Block]","Our cybersecurity risk assessment and management processes are implemented and maintained by certain members of Company management, including our Vice President of Information Technology who has over 15 years of extensive experience managing cybersecurity programs, who reports into our Chief Operating and Financial Officer. The Vice President of Information Technology is responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company's overall risk management strategy, and communicating key priorities to relevant personnel. The Chief Operating and Financial Officer is responsible for approving budgets, aiding in the preparation for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports."]
["Cybersecurity Risk Management Positions or Committees Responsible [Flag]","true"]
["Cybersecurity Risk Management Positions or Committees Responsible [Text Block]","The Chief Operating and Financial Officer is responsible for approving budgets, aiding in the preparation for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports."]
["Cybersecurity Risk Management Expertise of Management Responsible [Text Block]","The Vice President of Information Technology is responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company's overall risk management strategy, and communicating key priorities to relevant personnel."]
["Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]","The Chief Operating and Financial Officer collaborates with our incident response team, which includes members of our in-house IT, facilities, human resources, regulatory, legal, and communications teams, to address and resolve reported cybersecurity incidents. Olema’s incident response procedures mandate reporting certain types of cybersecurity incidents to the Audit Committee and other agencies as required by law."]
["Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]","true"]

{"sheet":"Pay vs Performance Disclosure","index":10,"n_rows":4,"n_cols":3,"rows_kept":4,"merged":[[0,0,1,0],[0,1,0,2]]}
["Pay vs Performance Disclosure - USD ($) $ in Thousands","12 Months Ended"]
[null,"Dec. 31, 2024","Dec. 31, 2023"]
["Pay vs Performance Disclosure"," "," "]
["Net Income (Loss)",{"v":-129474,"d":"$ (129,474)"},{"v":-96655,"d":"$ (96,655)"}]

{"sheet":"Insider Trading Arrangements","index":11,"n_rows":7,"n_cols":2,"rows_kept":7,"merged":[[0,0,1,0]]}
["Insider Trading Arrangements","3 Months Ended"]
[null,"Dec. 31, 2024"]
["Trading Arrangements, by Individual"," "]
["Rule 10b5-1 Arrangement Adopted","false"]
["Non-Rule 10b5-1 Arrangement Adopted","false"]
["Rule 10b5-1 Arrangement Terminated","false"]
["Non-Rule 10b5-1 Arrangement Terminated","false"]

{"sheet":"Nature of the Business and Basi","index":12,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Nature of the Business and Basis of Presentation","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Organization, Consolidation and Presentation of Financial Statements [Abstract]"," "]
["Nature of the Business and Basis of Presentation","1. Nature of the Business and Basis of Presentation Olema Pharmaceuticals, Inc. (“Olema” or the “Company”) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation targeted therapies for women’s cancers. The Company is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. The Company's wholly-owned, lead product candidate, palazestrant (OP-1250), is a novel, orally-available small molecule with dual activity as both a complete estrogen receptor (\"ER\") antagonist (\"CERAN\") and selective ER degrader (\"SERD\"). In addition to its lead product candidate, Olema is developing a potent KAT6 inhibitor (OP-3136). The Company is located in San Francisco, California and was incorporated in Delaware on August 7, 2006, under the legal name of CombiThera, Inc. and on March 25, 2009, was renamed Olema Pharmaceuticals, Inc. The Company’s principal operations are based in San Francisco, California, and it has operations in Cambridge, Massachusetts. Olema Oncology Australia Pty Ltd was incorporated on January 6, 2021, and is a wholly-owned subsidiary of the Company (collectively with Olema Pharmaceuticals, Inc., referred to as “Olema” or the “Company” herein). It operates in one business segment and therefore has only one reportable segment. The Company is subject to risks and uncertainties common to late-stage companies in the biopharmaceutical industry, including, but not limited to, successful discovery and development of its product candidates, development by competitors of new technological innovations, dependence on key personnel, the ability to attract and retain qualified employees, protection of proprietary technology, compliance with governmental regulations, the impact of geopolitical and macroeconomic events discussed in further detail below, the ability to secure additional capital to fund operations and commercial success of its product candidates. Palazestrant, OP-3136 and any future product candidates the Company may develop will require extensive non-clinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. Liquidity The Company had $ 434.1 million of cash, cash equivalents and marketable securities at December 31, 2024 , in addition to an available balance of $ 25.0 million under the Loan and Security Agreement dated as of September 5, 2023 (the “Original Loan Agreement”), by and between the Company, as borrower, and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (the “Bank”), as amended by the First Amendment to Loan and Security Agreement, dated June 28, 2024, by and between the Company and the Bank (the \"Amendment,\" and the Original Loan Agreement as amended by the Amendment, the \"Loan Agreement\"). See Footnote 12. Commitments and Contingencies for details. Management believes that the Company’s cash, cash equivalents, marketable securities, and the amounts available under the Loan Agreement will be sufficient to fund the Company’s current operating plan for at least the next 12 months from the filing date of these consolidated financial statements. Private Placement On November 29, 2024, the Company entered into a securities purchase agreement for a private placement of (i) 19,928,875 shares of the Company’s common stock at a price of $ 9.08 per share and (ii) pre-funded warrants to purchase up to an aggregate of 7,604,163 shares of the Company's common stock at a price of $ 9.0799 per pre-funded warrant, which represents the per share purchase price of the Company's common stock sold in the private placement less the $ 0.0001 per share exercise price for each pre-funded warrant to selected institutional and accredited investors (the “2024 Private Placement”). The aggregate gross proceeds for the 2024 Private Placement were approximately $ 250.0 million. After deducting offering expenses related to the 2024 Private Placement of approximately $ 6.5 million (the remaining $ 6.5 million was included in Other current liabilities in the consolidated balance sheets) , the net proceeds to the Company from the 2024 Private Placement were approximately $ 243.5 million. On September 5, 2023, the Company entered into a stock purchase agreement for a private placement of 13,211,381 shares of our common stock, at a price of $ 9.84 per share, to selected institutional and accredited investors (the \"2023 Private Placement\"), resulting in gross proceeds of approximately $ 130.0 million. After deducting offering expenses related to the 2023 Private Placement of approximately $ 0.3 million, the net proceeds to the Company from the 2023 Private Placement were approximately $ 129.7 million. At-The-Market Offering On January 5, 2024, the Company entered into a sales agreement (the “2024 Sales Agreement”) with Cowen and Company, LLC (\"Cowen and Company”) as sales agent, pursuant to which the Company may offer and sell, from time to time, shares of the Company's common stock, having an aggregate offering price of up to $ 150.0 million (the “2024 ATM Shares”). The sales of the 2024 ATM Shares will be made by any method permitted that is deemed to be an \"at-the-market\" equity offering as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (\"Securities Act\"), including sales made directly on or through the Nasdaq Global Select Market. The Company agreed to pay Cowen and Company a commission of up to 3.0 % of the aggregate gross proceeds from any 2024 ATM Shares sold by Cowen and Company. During the year ended December 31, 2024, the Company issued 1,772,278 shares of the Company's common stock under the 2024 Sales Agreement at a weighted-average price of $ 13.19 for net proceeds of $ 22.8 million after deducting related issuance costs. As of December 31, 2024, approximately $ 126.6 million remained available for issuance under the 2024 Sales Agreement. On January 6, 2025, the Company entered into a sales agreement (the \"2025 Sales Agreement\") with TD Securities (USA) LLC, (\"TD Cowen\") as sales agent, pursuant to which the Company may offer and sell, from time to time, shares of the Company's common stock, having an aggregate offering price of up to $ 150.0 million (the “2025 ATM Shares”). The 2025 Sales Agreement replaces the prior 2024 Sales Agreement. The sales of the 2025 ATM Shares will be made by any method permitted that is deemed to be an \"at-the-market\" equity offering as defined in Rule 415(a)(4) promulgated under the Securities Act, including sales made directly on or through the Nasdaq Global Select Market. The Company has agreed to pay TD Cowen a commission of up to 3.0 % of the aggregate gross proceeds from any 2025 ATM Shares sold by TD Cowen. Impact of Geopolitical and Macroeconomic Events Global economic and business activities continue to face widespread uncertainty related to the geopolitical and macroeconomic environment, generally, including economic uncertainty, market volatility, labor shortages, tariffs and trade tensions, the ongoing conflicts between Ukraine and Russia and in the Middle East, as well as any related political or economic responses and counter-responses or otherwise by various global actors, inflation rates and the responses by central banking authorities to control such inflation, monetary supply shifts and related financial instability. The extent of the impact of these factors on the Company’s operational and financial performance, including its ability to execute its business strategies and initiatives in the expected time frame, will depend on future developments, which are uncertain and cannot be predicted. Any continued or renewed disruption resulting from these factors could negatively impact the Company’s business. The Company continues to monitor the impact of these geopolitical and macroeconomic factors on its results of operations, financial condition and cash flows."]

{"sheet":"Summary of Significant Accounti","index":13,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Summary of Significant Accounting Policies","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Accounting Policies [Abstract]"," "]
["Summary of Significant Accounting Policies",{"$cut":{"chars":24561,"head":"2. Summary of Significant Accounting Policies Basis of Presentation and Consolidation The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding financial reporting, and the instructions to Form 10-K and Article 10 of Regulation S-X. These consolidated financial statements include the accounts of Olema Pharmaceuticals, Inc. and its wholly owned subsidiary, Olema Oncology Australia Pty Ltd. All intercompany balances and transactions have been eliminated upon consolidation. Use of Estimates The accompanying consolidated financial statements are prepared in accordance with GAAP. The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Significant areas that require management’s estimates include accruals of research and development expenses, including accrual of research contract costs, stock-based compensation assumptions, including the fair value of common stock. On an ongoing basis, the Company evaluates its estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Cash and Cash Equivalents Cash and cash equivalents are defined as short-term, highly liquid investments with original maturities of 90 days or fewer at the date of purchase. Cash deposits are all in reputable financial institutions in the United States as of December 31, 2024 and 2023 . Cash and cash equivalents consisted of cash on deposit with U.S. banks, including the Company’s bank account for its Australia subsidiary, denominated in U.S. dollars and Australian dollars and investments in interest bearing money market funds. Marketable Securities All marketable securities have been classified as “available-for-sale” and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments at the time of purchase and reevaluates such designation as of each balance sheet date. Unrealized gains and losses are excluded from net loss and are reported as a component of comprehensive loss. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in interest income. The cost of securities sold is based on the specific-identification method. Interest earned on marketable securities is included in interest income. The Company periodically assesses its available-for-sale marketable securities for other-than-temporary impairment. For debt securities in an unrealized loss position, the Company first considers its intent to sell, or whether it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis. If either of these criteria are met, the amortized cost basis of such debt securities is written down to fair value through other expense. For debt securities in an unrealized loss position that do not meet the aforementioned criteria, the Company assesses whether the decline in the fair value of such debt securities has resulted from credit losses or other factors. The Company considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and any adverse conditions specifically related to the securities, among other factors. If this assessment indicates that a credit loss may exist, the Company then compares the present value of cash flows expected to be collected from such securities to their amortiz"}}]

{"sheet":"Fair Value Measurement","index":14,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Fair Value Measurement","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Fair Value Disclosures [Abstract]"," "]
["Fair Value Measurement","3. Fair Value Measurement The Company assesses the fair value of financial instruments based on the provisions of ASC 820, Fair Value Measurements. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: • Level 1 — Inputs are unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date. • Level 2 — Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 — Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.\nDecember 31, 2024\n(in thousands) Level 1 Level 2 Level 3 Total\nFinancial Assets\nCash $ 6,489 $ — $ — $ 6,489\nMoney market funds 118,955 — — 118,955\nCommercial paper — 109,432 — 109,432\nCorporate bonds 43,409 — 43,409\nU.S. government treasury bills 144,741 — — 144,741\nGovernment-sponsored enterprise securities — 11,714 — 11,714\nTotal $ 270,185 $ 164,555 $ — $ 434,740\nDecember 31, 2024\nGross Gross\nAmortized Unrealized Unrealized Estimated\n(in thousands) Cost Gains Losses Fair Value\nFinancial Assets\nCash and cash equivalents $ 142,706 $ 4 $ — $ 142,710\nShort-term marketable securities (<12 months to maturity) 219,062 185 ( 57 ) 219,190\nLong-term marketable securities (>12 months to maturity) 72,829 53 ( 42 ) 72,840\nTotal $ 434,597 $ 242 $ ( 99 ) $ 434,740\nDecember 31, 2023\n(in thousands) Level 1 Level 2 Level 3 Total\nFinancial Assets\nCash $ 3,570 $ — $ — $ 3,570\nMoney market funds 59,280 — — 59,280\nCommercial paper — 105,017 — 105,017\nCorporate bonds — 12,627 — 12,627\nU.S. government treasury bills 60,012 — — 60,012\nGovernment-sponsored enterprise securities — 21,606 — 21,606\nTotal $ 122,862 $ 139,250 $ — $ 262,112\nDecember 31, 2023\nGross Gross\nAmortized Unrealized Unrealized Estimated\n(in thousands) Cost Gains Losses Fair Value\nFinancial Assets\nCash and cash equivalents $ 68,844 $ — $ — $ 68,844\nShort-term marketable securities (<12 months to maturity) 169,966 176 ( 8 ) 170,134\nLong-term marketable securities (>12 months to maturity) 22,955 179 — 23,134\nTotal $ 261,765 $ 355 $ ( 8 ) $ 262,112 The Company considers its marketable securities with maturities beyond one year as current assets, based on their highly liquid nature and because such marketable securities represent the investment of cash that is available for current operations. The Company considers its investment portfolio of marketable securities to be available-for-sale. The Company periodically reviews its available-for-sale marketable securities for other-than-temporary impairment. The Company considers factors such as the duration, severity and the reason for the decline in value, the potential recovery period and its intent to sell. For debt securities, the Company also considers whether (i) it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis, and (ii) the amortized cost basis cannot be recovered as a result of credit losses. There were no marketable securities that have been in a consecutive loss position for more than 12 months as of December 31, 2024. During the year ended December 31, 2024, the Company did not recognize any other-than-temporary impairment loss. As of December 31, 2024 , there was no allowance for losses on available-for-sale debt securities attributable to credit risk. As of December 31, 2024 , all of the Company’s cash and cash equivalents consisted of cash on deposit with U.S. banks denominated in U. S. dollars and Australian dollars."]

{"sheet":"Prepaid Expenses and Other Curr","index":15,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Prepaid Expenses and Other Current Assets","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Prepaid Expense and Other Assets, Current [Abstract]"," "]
["Prepaid Expenses and Other Current Assets","4. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following (in thousands):\nDecember 31, December 31,\n2024 2023\nInterest receivable $ 2,120 $ 673\nPrepaid insurance 1,033 1,239\nPrepaid subscriptions and licenses 728 255\nPrepaid clinical development costs 140 858\nOther 366 190\nReimbursable research and development costs from a collaboration partner — 1,491\nTotal $ 4,387 $ 4,706 "]

{"sheet":"Other Assets and Long-Term Depo","index":16,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Other Assets and Long-Term Deposits","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Assets [Abstract]"," "]
["Other Assets and Long-Term Deposits","5. Other Assets and Long-Term Deposits Other assets and long-term deposits consisted of the following (in thousands):\nDecember 31, December 31,\n2024 2023\nClinical development project deposits $ 9,263 $ 6,688\nProperty and equipment, net 746 968\nSystem implementation costs 683 —\nSecurity deposits 485 485\nOther 15 —\nTotal $ 11,192 $ 8,141 "]

{"sheet":"Other Current Liabilities","index":17,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Other Current Liabilities","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Other Liabilities, Current [Abstract]"," "]
["Other Current Liabilities","6. Other Current Liabilities Other current liabilities consisted of the following (in thousands):\nDecember 31, December 31,\n2024 2023\nAccrued research and development related costs $ 22,768 $ 11,322\nAccrued professional fees 7,545 903\nAccrued employee bonuses 5,661 5,465\nAccrued payroll related costs 111 172\nAccrued taxes 41 73\nTotal $ 36,126 $ 17,935 "]

{"sheet":"Common Stock","index":18,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Common Stock","12 Months Ended"]
[null,"Dec. 31, 2023"]
["Equity [Abstract]"," "]
["Common Stock","7. Common Stock As of each of the balance sheet dates below, the Company had reserved shares of common stock for issuance in connection with the following:\nDecember 31, December 31,\n2024 2023\nOptions outstanding under the 2014 Stock Plan 1,875,140 1,875,140\nOptions outstanding under the 2020 Equity Incentive Plan 7,786,735 5,669,961\nOptions outstanding under the 2022 Inducement Plan 1,691,182 1,125,641\nShares available for future grant under the 2020 Equity Incentive Plan and the 2022 Inducement Plan 2,056,300 2,497,813\nShares available for the 2020 Employee Stock Purchase Plan 1,122,615 684,497\nUnvested performance-based restricted stock unit awards outstanding under the 2020 Equity Incentive Plan — 403,000\nUnvested restricted stock awards outstanding under the 2014 Stock Plan — 80,703\nShares available for issuance related to pre-funded warrants 11,024,163 —\n25,556,135 12,336,755 Pre-Funded Warrants In December 2024, the Company issued pre-funded warrants to purchase up to 7,604,163 shares of the Company's common stock in the 2024 Private Placement at $ 9.07998 per share of the common stock, less the $ 0.0001 per share exercise price of each warrant. Also, in December 2024, the Company issued pre-funded warrants to purchase up to 3,420,000 shares of the Company's common stock in exchange of 3,420,000 shares of the Company's common stock previously held by investors. The warrants were recorded as a component of stockholders’ equity within additional paid-in capital and have no expiration date. "]

{"sheet":"Stock-Based Compensation","index":19,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Stock-Based Compensation","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Share-Based Payment Arrangement [Abstract]"," "]
["Stock-Based Compensation","8. Stock-Based Compensation In 2014, the Company’s Board of Directors (the “Board”) and stockholders approved and adopted the Company’s 2014 Stock Plan (the “2014 Plan”). The 2014 Plan permitted the grant of options and restricted stock awards (including restricted stock purchase rights and restricted stock bonus awards). The 2014 Plan was terminated on the date the Company’s 2020 Equity Incentive Plan (the “2020 Plan”), which is described below, became effective, and since that date, no additional awards have been or will be made pursuant to the 2014 Plan. However, any outstanding awards granted under the 2014 Plan will remain outstanding, subject to the terms of the 2014 Plan award agreements, until such outstanding options are exercised or until any awards terminate or expire by their terms. In 2020, the Board and the Company’s stockholders approved and adopted the 2020 Plan. The 2020 Plan permits the grant of options, restricted stock awards, stock appreciation rights, restricted stock unit awards, performance awards, and other awards. The maximum number of shares of common stock that initially issuable under the 2020 Plan was a number not to exceed 6,494,510 shares of the Company’s common stock, which is the sum of (i) 2,152,080 new shares, plus (ii) an additional number of shares not to exceed 4,342,430 shares, consisting of any shares of the Company’s common stock subject to outstanding stock options or other stock awards granted under the 2014 Plan that, on or after the date on which the 2020 Plan became effective, terminated or expired prior to exercise or settlement; were not issued because the award was settled in cash; were forfeited because of the failure to vest; or were reacquired or withheld (or not issued) to satisfy a tax withholding obligation or the purchase or exercise price. In addition, the number of shares of the Company’s common stock reserved for issuance under the 2020 Plan automatically increases on January 1 of each year for a period of ten years , beginning on January 1, 2021 and continuing through January 1, 2030, in an amount equal to the lesser of (1) 5 % of the total number of shares of the Company’s common stock outstanding on December 31 of the immediately preceding year, or (2) a lesser number of shares determined by the Board no later than December 31 of the immediately preceding year. In 2022, the Board approved and adopted the Company’s 2022 Inducement Plan (the “2022 Inducement Plan”). Under the 2022 Inducement Plan, initially 2,000,000 shares of common stock were reserved for issuance. The 2022 Inducement Plan permits the grant of options, restricted stock awards, stock appreciation rights, restricted stock unit awards, performance awards, and other awards. The exercise price for each option and stock appreciation right shall be established at the discretion of the Board, provided that the exercise price of a stock option will not be less than 100 % of the fair market value of the Company’s common stock on the date of grant. Specific vesting for stock options and stock appreciation rights is service related and determined in each award agreement, where stock options and stock appreciation rights are fully vested at the grant date or follow a graded vesting schedule. Stock options and stock appreciation rights granted under the plans generally expire ten years after the date of grant. Stock Option Valuation The fair value of stock option grants is estimated using the Black-Scholes option-pricing model. The Company lacks company-specific historical and implied volatility information. Therefore, it estimated its expected stock volatility based on the historical volatility of a publicly traded set of peer companies in addition to its own historical volatility. For options with service-based vesting conditions, the expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The expected term of stock options granted to non-employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is 0 % since the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. The assumptions that the Company used to determine the estimated grant-date fair value of stock options granted to employees and directors under the 2020 Plan and the 2022 Inducement Plan were as follows, presented as a weighted average:\nDecember 31, December 31,\n2024 2023\nRisk-free interest rate 3.91 % 3.64 %\nExpected term (in years) 6.03 6.02\nExpected volatility 85.00 % 86.35 %\nExpected dividend yield — — Stock Option Activity The following table summarizes the stock option activity under the 2014 Plan, the 2020 Plan and the 2022 Inducement Plan:\nWeighted\nWeighted Average\nAverage Remaining Aggregate\nNumber of Exercise Contractual Intrinsic\nShares Price Term Value\n(in years) (in thousands)\nOutstanding as of December 31, 2023 8,670,742 $ 8.52 7.60 $ 61,749\nGranted 3,478,850 14.21 — —\nExercised (1) ( 460,744 ) 4.09 — —\nForfeited ( 335,791 ) 14.17 — —\nOutstanding as of December 31, 2024 11,353,057 $ 10.28 6.37 $ 7,519\nOptions vested and exercisable as of December 31, 2024 6,376,793 $ 9.41 5.05 $ 5,958\nOptions expected to vest as of December 31, 2024 4,976,264 $ 11.40 8.05 $ 1,561 (1) Exercised amount includes shares returned for taxes withheld for exercise and net transactions. The weighted-average grant-date fair value per share of options granted during the years ended December 31, 2024 and 2023 was $ 10.40 and $ 4.37 , respectively. For the years ended December 31, 2024 and 2023 , there were 2,213,715 and 2,329,483 shares vested, respectively. The weighted-average grant date fair value per share of options vested during the years ended December 31, 2024 and 2023 was $ 6.58 and $ 6.97 , respectively. The total fair value of options vested during the years ended December 31, 2024 and 2023 was $ 14.6 million and $ 16.2 million, respectively. The aggregate intrinsic value of options exercised during the years ended December 31, 2024 and 2023 was $ 3.3 million and $ 3.5 million, respectively. As of December 31, 2024 , the total unrecognized compensation expense related to unvested options was $ 34.5 million, which the Company expects to recognize over an estimated weighted average period of 2.61 years. Restricted Stock Awards The following table summarizes the restricted stock awards (the RSAs) activity under the 2014 Plan during the year ended December 31, 2024:\nNumber of Shares Grant Date Fair Value\nUnvested restricted stock as of December 31, 2023 92,659 $ 2.40\nGranted —\nVested ( 92,659 ) 2.40\nForfeited —\nUnvested restricted stock as of December 31, 2024 — $ — The total grant date fair value of the RSAs vested during the year ended December 31, 2024, was $ 0.2 million. As of December 31, 2024, the was no unrecognized compensation expense related to the RSAs. The Company recorded s tock-based compensation expense of $ 0.2 million related to the vested shares of restricted stock awards for the year ended December 31, 2024. Performance-Based Restricted Stock Unit Awards In November 2022, the Company granted to certain employees 710,000 shares of performance-based restricted stock unit awards (the PSUs) under the 2020 Plan as consideration for services subject to performance conditions with a fair value based on the closing price of the underlying common stock on the date of grant. Pursuant to the terms of the PSUs, 65 % of each PSU vests upon certification by the Compensation Committee of the Company of achieving a pre-determined performance goal by June 30, 2024, and 35 % of each PSU vests upon certification by the Compensation Committee of the Company of achieving a pre-determined performance goal by June 30, 2024. The performance goal related to the 35 % tranche of the PSUs was met and related stock-based compensation expense was recorded in 2023. In June 2024, pursuant to the terms of the PSUs, the Compensation Committee of the Company approved an extension of the achievement of the performance goal related to the 65 % tranche of the PSUs from June 30, 2024 to December 31, 2024. Expense recognition for PSUs commences when it is determined that attainment of the performance goal is met. As of December 31, 2024, the performance goal related to the 65 % tranche of the PSUs was met and related stock-based compensation expense of $ 1.4 million was recorded. As of December 31, 2023, the performance goal related to the 35 % tranche of the PSUs was met and related stock-based compensation expense of $ 0.7 million was recorded. The following table summarizes the performance-based restricted stock activity under the 2020 plan during the year ended December 31, 2024:\nNumber of Shares Grant Date Fair Value\nUnvested performance-based restricted stock as of December 31, 2023 403,000 $ 3.38\nGranted —\nVested ( 403,000 ) 3.38\nForfeited — —\nUnvested performance-based restricted stock as of December 31, 2024 — $ — 2020 Employee Stock Purchase Plan (ESPP) In 2020, the Board and the Company’s stockholders approved and adopted the ESPP. The ESPP permits eligible employees who elect to participate in an offering under the ESPP to have up to 15 % of their eligible earnings withheld, subject to certain limitations, to purchase shares of common stock pursuant to the ESPP. The price of the common stock purchased under the ESPP is equal to the lesser of (i) 85 % of the fair market value of a share of the Company’s common stock on the first day of an offering; or (ii) 85 % of the fair market value of a share of the Company’s common stock on the date of purchase. Each offering period is not to exceed 27 months and will include one or more purchase periods (each a Purchase Period) as approved by the Board in the offering. A total of 430,416 shares of common stock were initially reserved for issuance pursuant to the ESPP. Subsequently, the number of shares of the Company’s common stock reserved for issuance under the ESPP automatically increases on January 1 of each year for a period of up to ten years , commencing on January 1, 2021 and continuing through January 1, 2030, in amount equal to the lesser of (i) 1 % of the total number of shares of the Company’s common stock outstanding on December 31 of the preceding calendar year, (ii) 860,832 shares of common stock, or (iii) a lesser number of shares determined by the Board no later than December 31 of the preceding calendar year. The ESPP is a compensatory plan as defined by the authoritative guidance for stock-based compensation. The Company uses the Black-Scholes option-pricing model to estimate the fair value of stock offered under the ESPP. Stock-based compensation expense related to the ESPP was $ 0.6 million and $ 0.5 million for the years ended December 31, 2024 and 2023, respectively. Stock-Based Compensation Expense Stock-based compensation expense related to awards granted under the 2014 Plan, the 2020 Plan, the ESPP and the 2022 Inducement Plan was classified in the consolidated statements of operations and comprehensive loss as follows (in thousands):\nYears Ended December 31,\n2024 2023\nResearch and development $ 16,543 $ 11,769\nGeneral and administrative 6,039 5,487\nTotal $ 22,582 $ 17,256 "]

{"sheet":"Income Taxes","index":20,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Income Taxes","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Income Tax Disclosure [Abstract]"," "]
["Income Taxes","9. Income Taxes The reconciliation of the Federal statutory income tax (provision) benefit to the Company’s effective income tax provision is as follows (in thousands):\nYears Ended December 31,\n2024 2023\nFederal statutory income tax $ 27,309 $ 20,060\nState income taxes, net of federal tax benefit 8,550 6,133\nForeign research and development tax credit 2,210 1,411\nPermanent differences in non-tax-deductible executive compensation ( 3,348 ) ( 2,842 )\nPermanent differences in foreign jurisdiction ( 1,650 ) ( 1,013 )\nPermanent differences others ( 469 ) 323\nOther deferred items 351 750\nRate changes ( 90 ) ( 63 )\nValuation allowance ( 32,865 ) ( 24,761 )\nNet expense for income taxes $ ( 2 ) $ ( 2 ) Deferred income taxes reflect the net tax effects of loss and credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company’s deferred income tax assets and liabilities at December 31, 2024 and 2023 comprised the following (in thousands):\nAs of December 31,\n2024 2023\nDeferred tax assets:\nNet operating loss carryforwards $ 60,600 $ 44,705\nCapitalized research and development 35,639 20,562\nEquity compensation 6,963 5,105\nLease Liability 405 682\nOther 1,482 1,452\nTotal deferred tax assets $ 105,089 $ 72,506\nDeferred tax liabilities:\nFixed assets $ ( 215 ) $ ( 281 )\nRight-of-use assets ( 372 ) $ ( 646 )\nTotal deferred tax liabilities ( 587 ) ( 927 )\nValuation allowance ( 104,502 ) ( 71,579 )\nNet deferred tax assets $ — $ — In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on the level of historical operating results and the uncertainty of the economic conditions, the Company has recorded a valuation allowance of $ 104.5 million and $ 71.6 million at December 31, 2024 and 2023, respectively. The change in the valuation allowance for the year end December 31, 2024 was an increase of $ 32.9 million. At December 31, 2024 and 2023, the Company had Federal net operating losses (NOLs) of approximately $ 190.2 million and $ 150.8 million, and state NOLs of $ 296.7 million and $ 187.0 million, respectively. As a result of the Tax Act, as modified by the CARES Act, for U.S. income tax purposes, NOLs generated in tax years beginning before January 1, 2018 can still be carried forward for up to 20 years , but net operating losses generated for tax years beginning after December 31, 2017 are carryforward indefinitely and can be used to offset taxable income, but the deductibility of such Federal NOLs may be limited to 80 % of current year taxable income for tax years beginning on or after December 31, 2024. Of the total Federal NOLs of $ 190.2 million, $ 3.3 million will begin to expire in 2032 and $ 186.9 million will not expire. The state NOL carryover of $ 296.7 million will begin to expire in 2032. Pursuant to Internal Revenue Code (IRC) Sections 382 and 383, annual use of the Company’s net operating loss and research and development credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has not completed an ownership change analysis pursuant to IRC Section 382. If ownership changes within the meaning of IRC Section 382 are identified as having occurred, the amount of remaining tax attribute carryforwards available to offset future taxable income and income tax expense in future years may be significantly restricted or eliminated. Further, the Company’s deferred tax assets associated with such tax attributes could be significantly reduced upon realization of an ownership change within the meaning of IRC Section 382 that has occurred or may occur in the future. Any adjustment to the Company’s tax attributes as a result of an ownership change will result in a corresponding decrease to the valuation allowance recorded against the Company’s deferred tax assets. The Company’s valuation allowance increased during the years ended December 31, 2024 and 2023 due primarily to the generation of net operating losses, as follows (in thousands):\nYears Ended December 31,\n2024 2023\nValuation allowance at beginning of year $ 71,579 $ 47,427\nIncrease recorded to provision for income taxes 32,923 24,152\nValuation allowance at end of year $ 104,502 $ 71,579 The Company has not incurred any material interest or penalties as of the current reporting date with respect to income tax matters. The Company is subject to U.S. Federal and state income taxes. The Federal and state income tax returns for tax years prior to 2024 may remain open to examination as carry-forward attributes generated prior may be adjusted upon examination."]

{"sheet":"Net Loss Per Common Share","index":21,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Net Loss Per Common Share","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Earnings Per Share [Abstract]"," "]
["Net Loss Per Common Share","10. Net Loss Per Common Share Net Loss Per Common Share Basic and diluted net loss per common share was calculated as follows (in thousands, except share and per share amounts):\nYears Ended December 31,\n2024 2023\nNumerator:\nNet loss $ ( 129,474 ) $ ( 96,655 )\nDenominator:\nWeighted average shares used to compute net loss per share, basic and diluted* 58,743,522 45,247,098\nNet loss per share, basic and diluted $ ( 2.20 ) $ ( 2.14 )\n* reflects the weighted average effect of the pre-funded warrants issued on December 4, 2024 for basic and diluted net loss per share. The potentially dilutive shares that were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented are as follows:\nYears Ended December 31,\n2024 2023\nOptions to purchase common stock 11,353,057 8,670,742\nUnvested performance-based restricted stock units — 403,000\nUnvested restricted common stock — 80,703\nEmployee stock purchase plan contingently issuable — 13,988\n11,353,057 9,168,433 "]

{"sheet":"Lease","index":22,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Lease","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Leases [Abstract]"," "]
["Lease","11. Lease The Company leases certain of its facilities under non-cancellable operating leases expiring at various dates through 2026. On December 15, 2020, the Company entered into a lease agreement with Tennieh LLC to lease approximately 9,800 square feet of office and lab space in San Francisco, California (the Laboratory Lease Agreement). The Laboratory Lease Agreement is for a period of five years commencing approximately February 1, 2021 and ending January 31, 2026. According to the terms of the Laboratory Lease Agreement, the Company paid a $ 0.4 million security deposit and is required to pay monthly rent and common area charges. On August 17, 2023, the Company entered into a sublease agreement with Dropbox, Inc. to sublease approximately 6,713 square feet of office space in San Francisco, California (the Dropbox Sublease Agreement). The Dropbox Sublease Agreement is for a period of two years commencing on September 5, 2023 and ending December 31, 2025. According to the terms of the Dropbox Sublease Agreement, the Company paid a $ 0.1 million security deposit and is required to pay monthly rent and common area charges. The sublease was accounted for under Topic 842 and the Company recorded ROU asset and lease liability of $ 0.2 million and $ 0.2 million, respectively, in the accompanying consolidated financial statements. On August 23, 2023, the Company entered into a lease agreement with The Cambridge Redevelopment Authority to lease approximately 4,020 square feet of office space in Cambridge, Massachusetts (the Cambridge Lease Agreement). The Cambridge Lease Agreement is for a period of three years commencing on September 15, 2023 and ending September 14, 2026. According to the terms of the Cambridge Lease Agreement, the Company paid a less than $ 0.1 million security deposit and is required to pay monthly rent and common area charges. The lease was accounted for under Topic 842 and the Company recorded ROU asset and lease liability of $ 0.7 million and $ 0.7 million, respectively, in the accompanying consolidated financial statements. The following table summarizes total lease expense during the years ended December 31, 2024 and 2023 (in thousands):\nYears Ended December 31,\n2024 2023\nStraight-line operating lease expense $ 1,150 $ 1,297\nShort-term lease expense — 164\nVariable lease expense 382 140\nTotal operating lease expense $ 1,532 $ 1,601 The following table summarizes supplemental cash flow information during the year ended December 31, 2024 and 2023 (in thousands):\nYears Ended December 31,\n2024 2023\nCash paid for amounts included measurement of lease liabilities:\nOperating cash flows from operating leases $ 1,162 $ 1,231\nSupplemental noncash information on lease liability arising from obtaining a right-use-asset — 896 The following table summarizes the Company’s future minimum lease payments and reconciliation of lease liabilities as of December 31, 2024 (in thousands):\nYears Ended December 31,\n2025 $ 1,245\n2026 263\nTotal future minimum lease payments 1,508\nLess: Interest ( 79 )\nTotal lease liabilities at present value 1,429\nLease liabilities, current 1,172\nLease liabilities, non-current $ 257 The following table summarizes lease term and discount rate as of December 31, 2024 and 2023:\nYears Ended December 31,\n2024 2023\nWeighted-average remaining lease term (years) 1.27 2.25\nWeighted-average discount rate 9.00 % 9.00 %"]

{"sheet":"Commitments and Contingencies","index":23,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Commitments and Contingencies","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Commitments and Contingencies Disclosure [Abstract]"," "]
["Commitments and Contingencies",{"$cut":{"chars":24632,"head":"12. Commitments and Contingencies Clinical Trial Collaboration and Supply Agreement with Novartis On November 29, 2024, the Company entered into a Clinical Trial Collaboration and Supply Agreement (the Novartis Pharma Agreement) with Novartis Pharma AG (Novartis). Pursuant to the Agreement, Novartis will provide the Company with ribociclib drug supply for the Company’s planned Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib in ER+/HER2- frontline advanced or metastatic breast cancer (the \"OPERA-02 trial\"). Under the Agreement, the Company will supply (including manufacturing, packaging and labeling) palazestrant and letrozole for the OPERA-02 trial. Novartis will manufacture and supply (including primary packaging) the Company with a specified amount of ribociclib, which amount is expected to be sufficient for the OPERA-02 trial. The parties granted to each other a non-exclusive, royalty-free license under certain of the parties’ respective background patent rights and other technology to use the parties’ respective study drugs in research and development, solely to the extent reasonably needed for the other party’s activities in the collaboration. Any inventions developed in the performance of the clinical studies for the combined therapies (other than those specific to each component study drug) are jointly owned by the parties. Except as otherwise specified below, the Novartis Pharma Agreement does not grant any right of first negotiation to participate in future clinical trials, and each party retains all rights and ability to evaluate their respective compounds in any studies or clinical trials, either as a monotherapy or in combination with any other product or compound, in any therapeutic area. The parties retain their independent rights to commercialize their respective therapies both alone and with third parties. The Company granted Novartis a right of first negotiation with respect to (a) the grant to any person or entity any right, license or sublicense to exploit palazestrant, in any field or territory, other than to third party service providers, or (b) the sale or other transfer to any person or entity of palazestrant and any related assets (each referred to herein as an Olema Compound Transaction). If the Company desires to or does, at any time, (a) solicit or entertain any third party proposal or indication of interest with respect to an Olema Compound Transaction, or (b) negotiate (including in response to any proposal or indication of interest received by the Company), enter into or perform under, in each case, any written definitive agreement with a third party with respect to or that contemplates an Olema Compound Transaction, then the Company must provide written notice to Novartis regarding such Olema Compound Transaction, along with certain other specified information. Novartis will have 30 days after receipt of such notice to elect to enter into exclusive good faith negotiations with respect to such Olema Compound Transaction for a period of up to 120 days . If the Company’s board of directors (or a duly authorized board committee) determines that the Company should pursue or explore a change of control of the Company or sale of all or substantially all of its assets (an Olema Change of Control), other than in response to an unsolicited bona fide acquisition proposal (a Proposed Sale), the Company must promptly notify Novartis of such determination. In the event Novartis elects to engage in negotiations with the Company in respect of such Proposed Sale, then from the date such notice is given until 45 days after the later of (a) the date on which the foregoing notice is given to Novartis, (b) the date on which Novartis is given notice that a data room has been populated as required by the Novartis Pharma Agreement, and (c) entry by the Company and Novartis into a customary nondisclosure agreement, Novartis will have the exclusive right (but no obligation) to conduct due diligence on the Company and its business and negotiate with the Company and its representatives the defini"}}]

{"sheet":"Summary of Significant Accoun_2","index":24,"n_rows":20,"n_cols":2,"rows_kept":20,"merged":[[0,0,1,0]]}
["Summary of Significant Accounting Policies (Policies)","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Accounting Policies [Abstract]"," "]
["Basis of Presentation and Consolidation","Basis of Presentation and Consolidation The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding financial reporting, and the instructions to Form 10-K and Article 10 of Regulation S-X. These consolidated financial statements include the accounts of Olema Pharmaceuticals, Inc. and its wholly owned subsidiary, Olema Oncology Australia Pty Ltd. All intercompany balances and transactions have been eliminated upon consolidation."]
["Use of Estimates","Use of Estimates The accompanying consolidated financial statements are prepared in accordance with GAAP. The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Significant areas that require management’s estimates include accruals of research and development expenses, including accrual of research contract costs, stock-based compensation assumptions, including the fair value of common stock. On an ongoing basis, the Company evaluates its estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates."]
["Cash and Cash Equivalents","Cash and Cash Equivalents Cash and cash equivalents are defined as short-term, highly liquid investments with original maturities of 90 days or fewer at the date of purchase. Cash deposits are all in reputable financial institutions in the United States as of December 31, 2024 and 2023 . Cash and cash equivalents consisted of cash on deposit with U.S. banks, including the Company’s bank account for its Australia subsidiary, denominated in U.S. dollars and Australian dollars and investments in interest bearing money market funds."]
["Marketable Securities","Marketable Securities All marketable securities have been classified as “available-for-sale” and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments at the time of purchase and reevaluates such designation as of each balance sheet date. Unrealized gains and losses are excluded from net loss and are reported as a component of comprehensive loss. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in interest income. The cost of securities sold is based on the specific-identification method. Interest earned on marketable securities is included in interest income. The Company periodically assesses its available-for-sale marketable securities for other-than-temporary impairment. For debt securities in an unrealized loss position, the Company first considers its intent to sell, or whether it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis. If either of these criteria are met, the amortized cost basis of such debt securities is written down to fair value through other expense. For debt securities in an unrealized loss position that do not meet the aforementioned criteria, the Company assesses whether the decline in the fair value of such debt securities has resulted from credit losses or other factors. The Company considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and any adverse conditions specifically related to the securities, among other factors. If this assessment indicates that a credit loss may exist, the Company then compares the present value of cash flows expected to be collected from such securities to their amortized cost basis. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded through other expense, limited by the amount that the fair value is less than the amortized cost basis. Any additional impairment not recorded through an allowance for credit losses is recognized in other comprehensive loss. The Company has not recorded any impairments for its marketable securities."]
["Concentration of Credit Risk and Other Risks and Uncertainties","Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents, and marketable securities. The Company invests in a variety of financial instruments and, by its policy, limits these financial instruments to high credit quality securities issued by the U.S. government, U.S. government-sponsored agencies and highly rated banks and corporations, subject to certain concentration limits. The Company’s cash, cash equivalents, and marketable securities are held by financial institutions in the United States that management believes are of high credit quality. Amounts on deposit with individual banking institutions may at times exceed the limits insured by the Federal Deposit Insurance Corporation (“FDIC”); however, the Company has not experienced any losses on such deposits. The Company’s future results of operations involve a number of other risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company’s current and potential future product candidates, uncertainty of market acceptance of the Company’s product candidates, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships, dependence on key individuals or sole-source suppliers, and geopolitical and macroeconomic factors. The Company’s product candidates require approvals from the U.S. Food and Drug Administration (“FDA”) and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company were denied approval, approval was delayed or the Company was unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company."]
["Leases","Leases Under Accounting Standards Update (\"ASU\") 2026-12, Leases, Topic 842, (\"Topic 842\"), lessees are required to recognize for all leases (with the exception of short-term leases) at the commencement date: (1) a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and (2) a right-of-use (“ROU”) asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the consolidated statements of operations and comprehensive loss. At the inception of an arrangement, the Company determines if an arrangement is, or contains, a lease based on the facts and circumstances present in that arrangement. Lease classification, recognition, and measurement are then determined at the lease commencement date. For arrangements that contain a lease, the Company (i) identifies lease and non-lease components, (ii) determines the consideration in the contract, (iii) determines whether the lease is an operating or finance lease; and (iv) recognizes lease ROU assets and liabilities. Lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable and as such, the Company uses the incremental borrowing rate based on the information available at the lease commencement date, which represents an internally developed rate that would be incurred to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment. Most leases include options to renew and, or terminate the lease, which can impact the lease term. The exercise of these options is at the Company’s discretion. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. For any lease modification, the Company reassesses the lease classification, remeasures the related lease liability using an updated discount rate that reflects the modified lease term, and adjusts the related ROU asset under the lease modification guidance under Topic 842. The Company has operating leases for its research and development and office facilities. Fixed lease payments on operating leases are recognized over the expected term of the lease on a straight-line basis. Variable lease expenses that are not considered fixed are recognized as incurred. Fixed and variable lease expense on operating leases is recognized within operating expenses within our consolidated statements of operations and comprehensive loss. The Company elected to not apply the recognition requirements of Topic 842 to short-term leases with terms of 12 months or less. Additional information and disclosures required by Topic 842 are contained in Note 11 “Lease” in this Annual Report."]
["Research and Development Costs","Research and Development Costs Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred to discover, research and develop product candidates. These costs are recorded within research and development expenses in the consolidated statements of operations and include personnel expenses, stock-based compensation expenses, allocated general and administrative expenses, and external costs including fees paid to consultants and contract research organizations (“CROs”) and contract manufacturing organizations (“CMOs”), in connection with non-clinical studies and clinical trials, and other related clinical trial fees, such as for investigator fees, patient screening, laboratory work, clinical trial database management, clinical trial material management and statistical compilation and analysis. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are recorded as prepaid expenses and other current assets. Such amounts are recognized as an expense as the goods are delivered or the related services are performed. Costs incurred in obtaining technology licenses that do not meet the definition of a business are charged immediately to research and development expense if the technology licensed has not reached technological feasibility and has no alternative future uses. Reimbursements of certain costs associated with research activities performed under the agreement with Novartis Institutes for BioMedical Research, Inc. (“Novartis”) are recorded as a reduction of research and development expenses and as a receivable due from Novartis, which is recorded under prepaid expenses and other current assets in the accompanying consolidated financial statements, as described in Note 12, Commitments and Contingencies – Clinical Collaboration and Supply Agreement."]
["Research Contract Costs and Accruals","Research Contract Costs and Accruals The Company has from time to time entered into various research and development and other agreements with commercial firms, researchers, universities and others for provisions of goods and services. These agreements are generally cancelable, and the related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research and development costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the projects, studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ materially from the Company’s estimates. The Company’s historical accrual estimates have not been materially different from the actual costs."]
["Internal-Use Software","Internal-Use Software The Company capitalizes certain costs incurred for the development and implementation of computer software for internal-use. These costs generally relate to the implementation of the third-party developed software for the Company's regulatory and quality purposes. The Company capitalizes these costs when it is determined that it is probable that the project will be completed and the software will be used to perform the function intended, and the preliminary project stage is completed. Capitalized internal-use software development and implementation costs are included in Other assets and long-term deposits within the consolidated balance sheets. Capitalized implementation costs are amortized on a straight-line basis over the estimated useful lives of five years . Costs related to the preliminary project stage, post-implementation, training and maintenance are expensed as incurred."]
["Income Taxes","Income Taxes Income taxes are computed using the asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s consolidated financial statements. In estimating future tax consequences, the Company considers all expected future events other than enactment of changes in tax laws or rates. A valuation allowance is recorded, if necessary, to reduce net deferred tax assets to their realizable values if management does not believe it is more likely than not that the net deferred tax assets will be realized. As of December 31, 2024 and 2023, the Company has recorded full valuation allowance against its net deferred tax assets. The Company had no unrecognized tax benefits for the years ended December 31, 2024 and 2023, respectively. The Company may be subject to U.S. Federal, state, and local tax examinations by tax authorities for years before 2024, which may include adjustments to carry-forward attributes (see Note 9, “Income Taxes”). The Company’s policy is to recognize interest and penalties related to uncertain tax positions in the provision for income taxes. As of December 31, 2024 and 2023 , the Company had no accrued interest or penalties related to uncertain tax positions."]
["Comprehensive Loss","Comprehensive Loss Comprehensive loss includes net loss and other comprehensive (loss) gain for each period presented. Other comprehensive (loss) gain represents net unrealized (loss) gain on marketable securities."]
["Stock-Based Compensation","Stock-Based Compensation Stock-based compensation cost, including grants of stock options and restricted stock awards issued under the Company’s equity incentive plans and ESPP, is measured at the grant date based on the estimated fair value of the award and is recognized as an expense on a straight-line basis over the requisite service period, which is generally the vesting period. Stock-based compensation cost for performance-based restricted stock unit awards issued under the Company’s equity incentive plan is measured at the grant date based on the estimated fair value of the award, which is based on the closing stock price on the grant date, and is recognized as an expense when the Company determines that it is probable that the performance goals will be achieved, which the Company assess on a quarterly basis. The Company recognizes stock compensation in accordance with ASC 718, Compensation — Stock Compensation (“ASC 718”). The Company’s determination of the fair value of stock options with time-based vesting on the date of grant utilizes the Black-Scholes option-pricing model. The Company estimates volatility using stock prices of peer companies and its historical data, risk-free rates using the implied yield currently available on U.S. Treasury zero-coupon issues with a remaining term equal to the expected term, and dividend yield using the Company’s expectations and historical data. The Company uses the simplified method to calculate the expected term of employee stock option grants. Under the simplified method, the expected term is estimated to be the mid-point between the vesting date and the contractual term of the option. For awards with graded vesting, in which specified tranches of the options vest on different dates, the Company uses a single weighted average expected life to value the entire award, which is equal to the average of the weighted average vesting period of the award and the contractual term of the award. Equity instruments issued to non-employees are recorded at their fair value on the grant date and without subsequent remeasurement. The amount of stock-based compensation expense recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest, including awards with graded vesting. As part of the requirements of ASC 718, the Company has elected to account for forfeitures of stock option grants as they occur."]
["Foreign Currency Transactions","Foreign Currency Transactions The functional currency of Olema Oncology Australia Pty Ltd, the Company’s wholly-owned subsidiary, is the U.S. dollar. Accordingly, all monetary assets and liabilities of the subsidiary are remeasured into U.S. dollars at the current period-end exchange rates and non-monetary assets are remeasured using historical exchange rates. Income and expense elements are remeasured to U.S. dollars using the average exchange rates in effect during the period. Remeasurement gains and losses are recorded as other income (expense) on the consolidated statements of operations. The Company is subject to foreign currency risk with respect to its clinical and manufacturing contracts denominated in currencies other than the U.S. dollar, predominantly the Australian dollar and the Euro. Payments on contracts denominated in foreign currencies are made at the spot rate on the day of payment. Changes in the exchange rate between billing dates and payment dates are recorded within other income (expense) on the consolidated statements of operations."]
["Pre-funded Warrants","Pre-funded Warrants The Company issued pre-funded warrants in connection with the Purchase Agreement. The Company accounts for the pre-funded warrants as a freestanding equity-linked financial instrument that met the criteria for equity classification pursuant to Accounting Standards Codification 480, Distinguishing Liabilities from Equity (\"ASC 480\"), and ASC 815, Derivatives and Hedging (\"ASC 815\"). Accordingly, the Company recorded the pre-funded warrants as a component of stockholders' equity within additional paid-in capital. The Company valued the pre-funded warrants at issuance, concluding that their sales price approximated their fair value. See Note 7 for further disclosure. "]
["Net Loss Per Common Share","Net Loss Per Common Share Basic net loss per common share is computed by dividing the net loss per common share by the weighted average number of common shares outstanding for the period without consideration of common stock equivalents. Diluted net loss per common share is computed by adjusting net loss to reallocate undistributed earnings based on the potential impact of dilutive securities, and by dividing the diluted net loss by the weighted average number of common shares outstanding for the period, including potential dilutive common shares. For purpose of this calculation, outstanding stock options, including unvested early exercised options, unvested restricted stock awards, unvested performance-based restricted stock unit awards and contingently issuable common stock related to the 2020 Employee Stock Purchase Plan (the “ESPP”) are considered potential dilutive common shares. Basic shares outstanding includes the weighted average effect of the Company's outstanding pre-funded warrants, the exercise of which requires little or no consideration for the delivery of shares of common stock. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods as the inclusion of all potential common shares outstanding would have been anti-dilutive."]
["Segment Reporting","Segment Reporting The Company's chief operating decision maker (“CODM”), the Chief Executive Officer , manages its business activities as a single operating and reportable segment at the consolidated level. Accordingly, the Company's CODM uses consolidated net loss to measure segment loss, allocate resources and assess performance. Further, the CODM reviews and utilizes functional expenses (research and development, and general and administrative) at the consolidated level to manage the Company’s operations. Other segment items included in consolidated net loss is interest income, which is reflected in the consolidated statements of operations and comprehensive loss. "]
["Recent Accounting Pronouncements Adopted","Recent Accounting Pronouncements Adopted In August 2020, the Financial Accounting Standards Board (\"FASB\") issued Accounting Standards Update (\"ASU\") No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) , which simplifies the accounting for convertible instruments and equity-linked financial instruments in addition to amending the earnings per share (\"EPS\") guidance in ASC 260 to improve the consistency of the diluted EPS calculation. The standard addresses issues identified as a result of the complexity associated with applying U.S. GAAP for certain financial instruments with characteristics of liabilities and equity. The standard eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The standard is effective for public companies, excluding entities eligible to be smaller reporting companies, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the standard is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. The Company adopted ASU 2020-06 as of January 1, 2024 . The adoption did not make an impact on its consolidated financial statements. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”) , which requires all public entities, including public entities with a single reportable segment, to provide in interim and annual periods one or more measures of segment profit or loss used by the chief operating decision maker to allocate resources and assess performance. Additionally, the standard requires disclosures of significant segment expenses and other segment items as well as incremental qualitative disclosures. The Company adopted ASU 2023-07 effective January 1, 2024 , on a retrospective basis. The adoption of 2023-07 did not change the way that the Company identifies its reportable segments and, as a result, did not have a material impact on the Company’s segment-related disclosures. Refer to the Segment Reporting section in Note 2 \"Summary of Significant Accounting Policies\". Recent Accounting Pronouncements Not Yet Adopted In December 2023, the FASB issued a new income tax-related accounting guidance in ASU 2023-09, Improvements to Income Tax Disclosures. The standard requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. For public business entities, the new requirements will be effective for annual periods beginning after December 15, 2024. The guidance will be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company did not early adopt this guidance as of December 31, 2024. The Company does not expect the adoption of ASU 2023-09 to have a material impact on its consolidated financial statements."]

{"sheet":"Fair Value Measurement (Tables)","index":25,"n_rows":5,"n_cols":2,"rows_kept":5,"merged":[[0,0,1,0]]}
["Fair Value Measurement (Tables)","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Fair Value Disclosures [Abstract]"," "]
["Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis","December 31, 2024\n(in thousands) Level 1 Level 2 Level 3 Total\nFinancial Assets\nCash $ 6,489 $ — $ — $ 6,489\nMoney market funds 118,955 — — 118,955\nCommercial paper — 109,432 — 109,432\nCorporate bonds 43,409 — 43,409\nU.S. government treasury bills 144,741 — — 144,741\nGovernment-sponsored enterprise securities — 11,714 — 11,714\nTotal $ 270,185 $ 164,555 $ — $ 434,740\nDecember 31, 2023\n(in thousands) Level 1 Level 2 Level 3 Total\nFinancial Assets\nCash $ 3,570 $ — $ — $ 3,570\nMoney market funds 59,280 — — 59,280\nCommercial paper — 105,017 — 105,017\nCorporate bonds — 12,627 — 12,627\nU.S. government treasury bills 60,012 — — 60,012\nGovernment-sponsored enterprise securities — 21,606 — 21,606\nTotal $ 122,862 $ 139,250 $ — $ 262,112 "]
["Schedule of Financial Assets Reconciliation","December 31, 2024\nGross Gross\nAmortized Unrealized Unrealized Estimated\n(in thousands) Cost Gains Losses Fair Value\nFinancial Assets\nCash and cash equivalents $ 142,706 $ 4 $ — $ 142,710\nShort-term marketable securities (<12 months to maturity) 219,062 185 ( 57 ) 219,190\nLong-term marketable securities (>12 months to maturity) 72,829 53 ( 42 ) 72,840\nTotal $ 434,597 $ 242 $ ( 99 ) $ 434,740\nDecember 31, 2023\nGross Gross\nAmortized Unrealized Unrealized Estimated\n(in thousands) Cost Gains Losses Fair Value\nFinancial Assets\nCash and cash equivalents $ 68,844 $ — $ — $ 68,844\nShort-term marketable securities (<12 months to maturity) 169,966 176 ( 8 ) 170,134\nLong-term marketable securities (>12 months to maturity) 22,955 179 — 23,134\nTotal $ 261,765 $ 355 $ ( 8 ) $ 262,112 "]

{"sheet":"Prepaid Expenses and Other Cu_2","index":26,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Prepaid Expenses and Other Current Assets (Tables)","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Prepaid Expense and Other Assets, Current [Abstract]"," "]
["Schedule of Prepaid Expenses and Other Current Assets","Prepaid expenses and other current assets consisted of the following (in thousands):\nDecember 31, December 31,\n2024 2023\nInterest receivable $ 2,120 $ 673\nPrepaid insurance 1,033 1,239\nPrepaid subscriptions and licenses 728 255\nPrepaid clinical development costs 140 858\nOther 366 190\nReimbursable research and development costs from a collaboration partner — 1,491\nTotal $ 4,387 $ 4,706 "]

{"sheet":"Other Assets and Long-Term De_2","index":27,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Other Assets and Long-Term Deposits (Tables)","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Assets [Abstract]"," "]
["Schedule of Other Assets and Long-Term Deposits","Other assets and long-term deposits consisted of the following (in thousands):\nDecember 31, December 31,\n2024 2023\nClinical development project deposits $ 9,263 $ 6,688\nProperty and equipment, net 746 968\nSystem implementation costs 683 —\nSecurity deposits 485 485\nOther 15 —\nTotal $ 11,192 $ 8,141 "]

{"sheet":"Other Current Liabilities (Tabl","index":28,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Other Current Liabilities (Tables)","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Other Liabilities, Current [Abstract]"," "]
["Schedule of Other Current Liabilities","Other current liabilities consisted of the following (in thousands):\nDecember 31, December 31,\n2024 2023\nAccrued research and development related costs $ 22,768 $ 11,322\nAccrued professional fees 7,545 903\nAccrued employee bonuses 5,661 5,465\nAccrued payroll related costs 111 172\nAccrued taxes 41 73\nTotal $ 36,126 $ 17,935 "]

{"sheet":"Common Stock (Tables)","index":29,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Common Stock (Tables)","12 Months Ended"]
[null,"Dec. 31, 2023"]
["Equity [Abstract]"," "]
["Schedule of Common Stock Reserved for Issuance","As of each of the balance sheet dates below, the Company had reserved shares of common stock for issuance in connection with the following:\nDecember 31, December 31,\n2024 2023\nOptions outstanding under the 2014 Stock Plan 1,875,140 1,875,140\nOptions outstanding under the 2020 Equity Incentive Plan 7,786,735 5,669,961\nOptions outstanding under the 2022 Inducement Plan 1,691,182 1,125,641\nShares available for future grant under the 2020 Equity Incentive Plan and the 2022 Inducement Plan 2,056,300 2,497,813\nShares available for the 2020 Employee Stock Purchase Plan 1,122,615 684,497\nUnvested performance-based restricted stock unit awards outstanding under the 2020 Equity Incentive Plan — 403,000\nUnvested restricted stock awards outstanding under the 2014 Stock Plan — 80,703\nShares available for issuance related to pre-funded warrants 11,024,163 —\n25,556,135 12,336,755 "]

{"sheet":"Stock-Based Compensation (Table","index":30,"n_rows":10,"n_cols":2,"rows_kept":10,"merged":[[0,0,1,0]]}
["Stock-Based Compensation (Tables)","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"," "]
["Schedule of Fair Value Assumptions","The assumptions that the Company used to determine the estimated grant-date fair value of stock options granted to employees and directors under the 2020 Plan and the 2022 Inducement Plan were as follows, presented as a weighted average:\nDecember 31, December 31,\n2024 2023\nRisk-free interest rate 3.91 % 3.64 %\nExpected term (in years) 6.03 6.02\nExpected volatility 85.00 % 86.35 %\nExpected dividend yield — — "]
["Schedule of Stock Option Activity","The following table summarizes the stock option activity under the 2014 Plan, the 2020 Plan and the 2022 Inducement Plan:\nWeighted\nWeighted Average\nAverage Remaining Aggregate\nNumber of Exercise Contractual Intrinsic\nShares Price Term Value\n(in years) (in thousands)\nOutstanding as of December 31, 2023 8,670,742 $ 8.52 7.60 $ 61,749\nGranted 3,478,850 14.21 — —\nExercised (1) ( 460,744 ) 4.09 — —\nForfeited ( 335,791 ) 14.17 — —\nOutstanding as of December 31, 2024 11,353,057 $ 10.28 6.37 $ 7,519\nOptions vested and exercisable as of December 31, 2024 6,376,793 $ 9.41 5.05 $ 5,958\nOptions expected to vest as of December 31, 2024 4,976,264 $ 11.40 8.05 $ 1,561 (1) Exercised amount includes shares returned for taxes withheld for exercise and net transactions."]
["Summary of Restricted Stock Awards Activity and Performance-Based Restricted Stock Unit Awards","The following table summarizes the performance-based restricted stock activity under the 2020 plan during the year ended December 31, 2024:\nNumber of Shares Grant Date Fair Value\nUnvested performance-based restricted stock as of December 31, 2023 403,000 $ 3.38\nGranted —\nVested ( 403,000 ) 3.38\nForfeited — —\nUnvested performance-based restricted stock as of December 31, 2024 — $ — "]
["Schedule of Stock-based Compensation Expense","Stock-based compensation expense related to awards granted under the 2014 Plan, the 2020 Plan, the ESPP and the 2022 Inducement Plan was classified in the consolidated statements of operations and comprehensive loss as follows (in thousands):\nYears Ended December 31,\n2024 2023\nResearch and development $ 16,543 $ 11,769\nGeneral and administrative 6,039 5,487\nTotal $ 22,582 $ 17,256 "]
["Unvested restricted common stock"," "]
["Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"," "]
["Summary of Restricted Stock Awards Activity and Performance-Based Restricted Stock Unit Awards","The following table summarizes the restricted stock awards (the RSAs) activity under the 2014 Plan during the year ended December 31, 2024:\nNumber of Shares Grant Date Fair Value\nUnvested restricted stock as of December 31, 2023 92,659 $ 2.40\nGranted —\nVested ( 92,659 ) 2.40\nForfeited —\nUnvested restricted stock as of December 31, 2024 — $ — "]

{"sheet":"Income Taxes (Tables)","index":31,"n_rows":6,"n_cols":2,"rows_kept":6,"merged":[[0,0,1,0]]}
["Income Taxes (Tables)","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Income Tax Disclosure [Abstract]"," "]
["Schedule of Reconciliation of Federal Statutory Income Tax (Provision) Benefit to Effective Income Tax Provision","The reconciliation of the Federal statutory income tax (provision) benefit to the Company’s effective income tax provision is as follows (in thousands):\nYears Ended December 31,\n2024 2023\nFederal statutory income tax $ 27,309 $ 20,060\nState income taxes, net of federal tax benefit 8,550 6,133\nForeign research and development tax credit 2,210 1,411\nPermanent differences in non-tax-deductible executive compensation ( 3,348 ) ( 2,842 )\nPermanent differences in foreign jurisdiction ( 1,650 ) ( 1,013 )\nPermanent differences others ( 469 ) 323\nOther deferred items 351 750\nRate changes ( 90 ) ( 63 )\nValuation allowance ( 32,865 ) ( 24,761 )\nNet expense for income taxes $ ( 2 ) $ ( 2 )"]
["Schedule of Deferred Income Tax Assets and Liabilities","The Company’s deferred income tax assets and liabilities at December 31, 2024 and 2023 comprised the following (in thousands):\nAs of December 31,\n2024 2023\nDeferred tax assets:\nNet operating loss carryforwards $ 60,600 $ 44,705\nCapitalized research and development 35,639 20,562\nEquity compensation 6,963 5,105\nLease Liability 405 682\nOther 1,482 1,452\nTotal deferred tax assets $ 105,089 $ 72,506\nDeferred tax liabilities:\nFixed assets $ ( 215 ) $ ( 281 )\nRight-of-use assets ( 372 ) $ ( 646 )\nTotal deferred tax liabilities ( 587 ) ( 927 )\nValuation allowance ( 104,502 ) ( 71,579 )\nNet deferred tax assets $ — $ — "]
["Schedule of Valuation Allowance","The Company’s valuation allowance increased during the years ended December 31, 2024 and 2023 due primarily to the generation of net operating losses, as follows (in thousands):\nYears Ended December 31,\n2024 2023\nValuation allowance at beginning of year $ 71,579 $ 47,427\nIncrease recorded to provision for income taxes 32,923 24,152\nValuation allowance at end of year $ 104,502 $ 71,579 "]

{"sheet":"Net Loss Per Common Share (Tabl","index":32,"n_rows":5,"n_cols":2,"rows_kept":5,"merged":[[0,0,1,0]]}
["Net Loss Per Common Share (Tables)","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Earnings Per Share [Abstract]"," "]
["Schedule of Basic and Diluted Net Loss Per Common Share","Basic and diluted net loss per common share was calculated as follows (in thousands, except share and per share amounts):\nYears Ended December 31,\n2024 2023\nNumerator:\nNet loss $ ( 129,474 ) $ ( 96,655 )\nDenominator:\nWeighted average shares used to compute net loss per share, basic and diluted* 58,743,522 45,247,098\nNet loss per share, basic and diluted $ ( 2.20 ) $ ( 2.14 )\n* reflects the weighted average effect of the pre-funded warrants issued on December 4, 2024 for basic and diluted net loss per share. "]
["Schedule of Anti-dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share","The potentially dilutive shares that were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented are as follows:\nYears Ended December 31,\n2024 2023\nOptions to purchase common stock 11,353,057 8,670,742\nUnvested performance-based restricted stock units — 403,000\nUnvested restricted common stock — 80,703\nEmployee stock purchase plan contingently issuable — 13,988\n11,353,057 9,168,433 "]

{"sheet":"Lease (Tables)","index":33,"n_rows":7,"n_cols":2,"rows_kept":7,"merged":[[0,0,1,0]]}
["Lease (Tables)","12 Months Ended"]
[null,"Dec. 31, 2024"]
["Leases [Abstract]"," "]
["Summary of Total Lease Expense","The following table summarizes total lease expense during the years ended December 31, 2024 and 2023 (in thousands):\nYears Ended December 31,\n2024 2023\nStraight-line operating lease expense $ 1,150 $ 1,297\nShort-term lease expense — 164\nVariable lease expense 382 140\nTotal operating lease expense $ 1,532 $ 1,601 "]
["Summary of Supplemental Cash Flow Information","The following table summarizes supplemental cash flow information during the year ended December 31, 2024 and 2023 (in thousands):\nYears Ended December 31,\n2024 2023\nCash paid for amounts included measurement of lease liabilities:\nOperating cash flows from operating leases $ 1,162 $ 1,231\nSupplemental noncash information on lease liability arising from obtaining a right-use-asset — 896 "]
["Summary of Future Minimum Lease Payments","The following table summarizes the Company’s future minimum lease payments and reconciliation of lease liabilities as of December 31, 2024 (in thousands):\nYears Ended December 31,\n2025 $ 1,245\n2026 263\nTotal future minimum lease payments 1,508\nLess: Interest ( 79 )\nTotal lease liabilities at present value 1,429\nLease liabilities, current 1,172\nLease liabilities, non-current $ 257 "]
["Summary of Lease Term and Discount Rate","The following table summarizes lease term and discount rate as of December 31, 2024 and 2023:\nYears Ended December 31,\n2024 2023\nWeighted-average remaining lease term (years) 1.27 2.25\nWeighted-average discount rate 9.00 % 9.00 %"]

{"sheet":"Nature of the Business and Ba_2","index":34,"n_rows":45,"n_cols":7,"rows_kept":45,"merged":[[0,0,1,0],[0,5,0,6]]}
["Nature of the Business and Basis of Presentation - Additional Information (Details) $ / shares in Units, $ in Thousands",{"$nulls":4},"12 Months Ended"]
[null,"Jan. 06, 2025 USD ($)","Nov. 29, 2024 USD ($) $ / shares shares","Jan. 05, 2024 USD ($)","Sep. 05, 2023 USD ($) $ / shares shares","Dec. 31, 2024 USD ($) Segment $ / shares shares","Dec. 31, 2023 USD ($)"]
["Organization, Consolidation and Presentation of Financial Statements [Line Item]"," "," "," "," "," "," "]
["Number of operating segments | Segment"," "," "," "," ",{"v":1,"d":"1 "}," "]
["Number of reportable segments | Segment"," "," "," "," ",{"v":1,"d":"1 "}," "]
["Cash, cash equivalents and marketable securities"," "," "," "," ",{"v":434100,"d":"$ 434,100"}," "]
["Offering expenses of private placement"," "," "," "," "," ",{"v":264,"d":"$ 264"}]
["Net proceeds of private placement"," "," "," "," ",{"v":243501,"d":"$ 243,501"},{"v":129736,"d":"$ 129,736"}]
["Pre-Funded Warrants"," "," "," "," "," "," "]
["Organization, Consolidation and Presentation of Financial Statements [Line Item]"," "," "," "," "," "," "]
["Warrants to purchase aggregate common shares | shares"," ",{"v":7604163,"d":"7,604,163 "}," "," "," "," "]
["Exercise price of warrant | $ / shares"," ",{"v":0.0001,"d":"$ 0.0001"}," "," ",{"v":0.0001,"d":"$ 0.0001"}," "]
["Senior Secured Loan Facility"," "," "," "," "," "," "]
["Organization, Consolidation and Presentation of Financial Statements [Line Item]"," "," "," "," "," "," "]
["Amount available for draw down, Lenders discretion"," "," "," ",{"v":25000,"d":"$ 25,000"},{"v":25000,"d":"$ 25,000"}," "]
["Private Placement"," "," "," "," "," "," "]
["Organization, Consolidation and Presentation of Financial Statements [Line Item]"," "," "," "," "," "," "]
["Shares issued in private placement | shares"," ",{"v":19928875,"d":"19,928,875 "}," ",{"v":13211381,"d":"13,211,381 "}," "," "]
["Share price | $ / shares"," ",{"v":9.08,"d":"$ 9.08"}," ",{"v":9.84,"d":"$ 9.84"},{"v":9.07998,"d":"$ 9.07998"}," "]
["Gross proceeds of private placement"," ",{"v":250000,"d":"$ 250,000"}," ",{"v":130000,"d":"$ 130,000"}," "," "]
["Offering expenses of private placement"," ",{"v":6500,"d":"6,500 "}," ",{"v":300,"d":"300 "},{"v":12998,"d":"$ 12,998"}," "]
["Liability for stock issuance costs"," ",{"v":6500,"d":"6,500 "}," "," "," "," "]
["Net proceeds of private placement"," ",{"v":243500,"d":"$ 243,500"}," ",{"v":129700,"d":"$ 129,700"}," "," "]
["Private Placement | Pre-Funded Warrants"," "," "," "," "," "," "]
["Organization, Consolidation and Presentation of Financial Statements [Line Item]"," "," "," "," "," "," "]
["Purchase price | $ / shares"," ",{"v":9.0799,"d":"$ 9.0799"}," "," "," "," "]
["At-The-Market Offering"," "," "," "," "," "," "]
["Organization, Consolidation and Presentation of Financial Statements [Line Item]"," "," "," "," "," "," "]
["Offering expenses of private placement"," "," "," "," ",{"v":166,"d":"166 "}," "]
["Sales Agreement | At-The-Market Offering"," "," "," "," "," "," "]
["Organization, Consolidation and Presentation of Financial Statements [Line Item]"," "," "," "," "," "," "]
["Sale of stock consideration remained available for issuance"," "," "," "," ",{"v":126600,"d":"$ 126,600"}," "]
["Sales Agreement | Cowen and Company | At-The-Market Offering"," "," "," "," "," "," "]
["Organization, Consolidation and Presentation of Financial Statements [Line Item]"," "," "," "," "," "," "]
["Share price | $ / shares"," "," "," "," ",{"v":13.19,"d":"$ 13.19"}," "]
["Net proceeds from At-The-Market offering"," "," "," "," ",{"v":22800,"d":"$ 22,800"}," "]
["Issuance of shares under at-the-market offering | shares"," "," "," "," ",{"v":1772278,"d":"1,772,278 "}," "]
["Sales Agreement | Cowen and Company | At-The-Market Offering | Maximum"," "," "," "," "," "," "]
["Organization, Consolidation and Presentation of Financial Statements [Line Item]"," "," "," "," "," "," "]
["Offering price"," "," ",{"v":150000,"d":"$ 150,000"}," "," "," "]
["Aggregate gross proceeds commission"," "," ",{"v":0.03,"d":"3%"}," "," "," "]
["Sales Agreement | TD Cowen | At-The-Market Offering | Maximum | Subsequent Event"," "," "," "," "," "," "]
["Organization, Consolidation and Presentation of Financial Statements [Line Item]"," "," "," "," "," "," "]
["Offering price",{"v":150000,"d":"$ 150,000"}," "," "," "," "," "]
["Aggregate gross proceeds commission",{"v":0.03,"d":"3%"}," "," "," "," "," "]

{"sheet":"Summary of Significant Accoun_3","index":35,"n_rows":21,"n_cols":3,"rows_kept":21,"merged":[[0,0,1,0]]}
["Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Millions","12 Months Ended"]
[null,"Dec. 31, 2024","Dec. 31, 2023"]
["Significant Accounting Policies [Line Items]"," "," "]
["Unrecognized tax benefits",{"v":0,"d":"$ 0"},{"v":0,"d":"$ 0"}]
["Accrued interest or penalties",{"v":0,"d":"$ 0"}," "]
["Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]","srt:ChiefExecutiveOfficerMember"," "]
["Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description","CODM uses consolidated net loss to measure segment loss, allocate resources and assess performance."," "]
["Segment Reporting, Expense Information Used by CODM, Description","CODM reviews and utilizes functional expenses (research and development, and general and administrative) at the consolidated level to manage the Company’s operations."," "]
["ASU 2020-06"," "," "]
["Significant Accounting Policies [Line Items]"," "," "]
["Change in Accounting Principle, Accounting Standards Update, Adoption Date","Jan.  01,  2024"," "]
["Change in Accounting Principle, Accounting Standards Update, Adopted [true false]","true"," "]
["Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]","true"," "]
["ASU 2023-07"," "," "]
["Significant Accounting Policies [Line Items]"," "," "]
["Change in Accounting Principle, Accounting Standards Update, Adoption Date","Jan.  01,  2024"," "]
["Change in Accounting Principle, Accounting Standards Update, Adopted [true false]","true"," "]
["Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]","true"," "]
["Internal-Use Software"," "," "]
["Significant Accounting Policies [Line Items]"," "," "]
["Estimated useful lives (in years)","5 years"," "]

{"sheet":"Fair Value Measurement - Schedu","index":36,"n_rows":41,"n_cols":3,"rows_kept":41}
["Fair Value Measurement - Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Fair Value Recurring - USD ($) $ in Thousands","Dec. 31, 2024","Dec. 31, 2023"]
["Assets"," "," "]
["Cash",{"v":6489,"d":"$ 6,489"},{"v":3570,"d":"$ 3,570"}]
["Total",{"v":434740,"d":"434,740 "},{"v":262112,"d":"262,112 "}]
["Level 1"," "," "]
["Assets"," "," "]
["Cash",{"v":6489,"d":"6,489 "},{"v":3570,"d":"3,570 "}]
["Total",{"v":270185,"d":"270,185 "},{"v":122862,"d":"122,862 "}]
["Level 2"," "," "]
["Assets"," "," "]
["Total",{"v":164555,"d":"164,555 "},{"v":139250,"d":"139,250 "}]
["Money Market Funds"," "," "]
["Assets"," "," "]
["Cash",{"v":118955,"d":"118,955 "},{"v":59280,"d":"59,280 "}]
["Money Market Funds | Level 1"," "," "]
["Assets"," "," "]
["Cash",{"v":118955,"d":"118,955 "},{"v":59280,"d":"59,280 "}]
["Commercial Paper"," "," "]
["Assets"," "," "]
["Marketable securities",{"v":109432,"d":"109,432 "},{"v":105017,"d":"105,017 "}]
["Commercial Paper | Level 2"," "," "]
["Assets"," "," "]
["Marketable securities",{"v":109432,"d":"109,432 "},{"v":105017,"d":"105,017 "}]
["Corporate Bonds"," "," "]
["Assets"," "," "]
["Marketable securities",{"v":43409,"d":"43,409 "},{"v":12627,"d":"12,627 "}]
["Corporate Bonds | Level 2"," "," "]
["Assets"," "," "]
["Marketable securities",{"v":43409,"d":"43,409 "},{"v":12627,"d":"12,627 "}]
["U.S. Government Treasury Bills"," "," "]
["Assets"," "," "]
["Marketable securities",{"v":144741,"d":"144,741 "},{"v":60012,"d":"60,012 "}]
["U.S. Government Treasury Bills | Level 1"," "," "]
["Assets"," "," "]
["Marketable securities",{"v":144741,"d":"144,741 "},{"v":60012,"d":"60,012 "}]
["Government-sponsored Enterprise Securities"," "," "]
["Assets"," "," "]
["Marketable securities",{"v":11714,"d":"11,714 "},{"v":21606,"d":"21,606 "}]
["Government-sponsored Enterprise Securities | Level 2"," "," "]
["Assets"," "," "]
["Marketable securities",{"v":11714,"d":"$ 11,714"},{"v":21606,"d":"$ 21,606"}]

{"sheet":"Fair Value Measurement - Sche_2","index":37,"n_rows":23,"n_cols":3,"rows_kept":23}
["Fair Value Measurement - Schedule of Financial Assets Reconciliation (Details) - USD ($) $ in Thousands","Dec. 31, 2024","Dec. 31, 2023"]
["Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]"," "," "]
["Amortized Cost",{"v":434597,"d":"$ 434,597"},{"v":261765,"d":"$ 261,765"}]
["Gross Unrealized Gains",{"v":242,"d":"242 "},{"v":355,"d":"355 "}]
["Gross Unrealized Losses",{"v":-99,"d":"(99)"},{"v":-8,"d":"(8)"}]
["Estimated Fair Value",{"v":434740,"d":"434,740 "},{"v":262112,"d":"262,112 "}]
["Cash and Cash Equivalents"," "," "]
["Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]"," "," "]
["Amortized Cost",{"v":142706,"d":"142,706 "},{"v":68844,"d":"68,844 "}]
["Gross Unrealized Gains",{"v":4,"d":"4 "}," "]
["Estimated Fair Value",{"v":142710,"d":"142,710 "},{"v":68844,"d":"68,844 "}]
["Short-term Marketable Securities"," "," "]
["Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]"," "," "]
["Amortized Cost",{"v":219062,"d":"219,062 "},{"v":169966,"d":"169,966 "}]
["Gross Unrealized Gains",{"v":185,"d":"185 "},{"v":176,"d":"176 "}]
["Gross Unrealized Losses",{"v":-57,"d":"(57)"},{"v":-8,"d":"(8)"}]
["Estimated Fair Value",{"v":219190,"d":"219,190 "},{"v":170134,"d":"170,134 "}]
["Long-term Marketable Securities"," "," "]
["Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]"," "," "]
["Amortized Cost",{"v":72829,"d":"72,829 "},{"v":22955,"d":"22,955 "}]
["Gross Unrealized Gains",{"v":53,"d":"53 "},{"v":179,"d":"179 "}]
["Gross Unrealized Losses",{"v":-42,"d":"(42)"}," "]
["Estimated Fair Value",{"v":72840,"d":"$ 72,840"},{"v":23134,"d":"$ 23,134"}]

{"sheet":"Fair Value Measurement - Additi","index":38,"n_rows":5,"n_cols":3,"rows_kept":5}
["Fair Value Measurement - Additional Information (Details)","Dec. 31, 2024 USD ($) Security","Dec. 31, 2023 USD ($)"]
["Fair Value Disclosures [Abstract]"," "," "]
["Marketable securities in an unrealized loss position for more than 12 months | Security",{"v":0,"d":"0 "}," "]
["Total unrealized losses",{"v":99000,"d":"$ 99,000"},{"v":8000,"d":"$ 8,000"}]
["Allowance for losses on available-for-sale debt securities",{"v":0,"d":"$ 0"}," "]

{"sheet":"Property and Equipment, Net - S","index":39,"n_rows":3,"n_cols":3,"rows_kept":3}
["Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands","Dec. 31, 2024","Dec. 31, 2023"]
["Property, Plant and Equipment [Line Items]"," "," "]
["Property and equipment, net",{"v":746,"d":"$ 746"},{"v":968,"d":"$ 968"}]

{"sheet":"Prepaid Expenses and Other Cu_3","index":40,"n_rows":9,"n_cols":3,"rows_kept":9}
["Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands","Dec. 31, 2024","Dec. 31, 2023"]
["Prepaid Expense and Other Assets, Current [Abstract]"," "," "]
["Interest receivable",{"v":2120,"d":"$ 2,120"},{"v":673,"d":"$ 673"}]
["Prepaid insurance",{"v":1033,"d":"1,033 "},{"v":1239,"d":"1,239 "}]
["Prepaid subscriptions and licenses",{"v":728,"d":"728 "},{"v":255,"d":"255 "}]
["Prepaid clinical development costs",{"v":140,"d":"140 "},{"v":858,"d":"858 "}]
["Other",{"v":366,"d":"366 "},{"v":190,"d":"190 "}]
["Reimbursable research and development costs from a collaboration partner",{"v":0,"d":"0 "},{"v":1491,"d":"1,491 "}]
["Total",{"v":4387,"d":"$ 4,387"},{"v":4706,"d":"$ 4,706"}]

{"sheet":"Other Assets and Long-Term De_3","index":41,"n_rows":8,"n_cols":3,"rows_kept":8}
["Other Assets and Long-Term Deposits - Schedule of Other Assets and Long-Term Deposits (Details) - USD ($) $ in Thousands","Dec. 31, 2024","Dec. 31, 2023"]
["Assets [Abstract]"," "," "]
["Clinical development project deposits",{"v":9263,"d":"$ 9,263"},{"v":6688,"d":"$ 6,688"}]
["Property and equipment, net",{"v":746,"d":"746 "},{"v":968,"d":"968 "}]
["System implementation costs",{"v":683,"d":"683 "}," "]
["Security deposits",{"v":485,"d":"485 "},{"v":485,"d":"485 "}]
["Other",{"v":15,"d":"15 "}," "]
["Total",{"v":11192,"d":"$ 11,192"},{"v":8141,"d":"$ 8,141"}]

{"sheet":"Other Current Liabilities - Sch","index":42,"n_rows":8,"n_cols":3,"rows_kept":8}
["Other Current Liabilities - Schedule of Other Current Liabilities (Details) - USD ($) $ in Thousands","Dec. 31, 2024","Dec. 31, 2023"]
["Other Liabilities, Current [Abstract]"," "," "]
["Accrued research and development related costs",{"v":22768,"d":"$ 22,768"},{"v":11322,"d":"$ 11,322"}]
["Accrued professional fees",{"v":7545,"d":"7,545 "},{"v":903,"d":"903 "}]
["Accrued employee bonuses",{"v":5661,"d":"5,661 "},{"v":5465,"d":"5,465 "}]
["Accrued payroll related costs",{"v":111,"d":"111 "},{"v":172,"d":"172 "}]
["Accrued taxes",{"v":41,"d":"41 "},{"v":73,"d":"73 "}]
["Total",{"v":36126,"d":"$ 36,126"},{"v":17935,"d":"$ 17,935"}]

{"sheet":"Common Stock - Schedule of Comm","index":43,"n_rows":27,"n_cols":4,"rows_kept":27}
["Common Stock - Schedule of Common Stock Reserved for Issuance (Details) - shares","Dec. 31, 2024","Dec. 31, 2023","Dec. 31, 2020"]
["Class of Stock [Line Items]"," "," "," "]
["Common stock reserved shares for issuance",{"v":25556135,"d":"25,556,135 "},{"v":12336755,"d":"12,336,755 "}," "]
["Options Outstanding Under the 2014 Stock Plan"," "," "," "]
["Class of Stock [Line Items]"," "," "," "]
["Common stock reserved shares for issuance",{"v":1875140,"d":"1,875,140 "},{"v":1875140,"d":"1,875,140 "}," "]
["Options Outstanding Under the 2020 Equity Incentive Plan"," "," "," "]
["Class of Stock [Line Items]"," "," "," "]
["Common stock reserved shares for issuance",{"v":7786735,"d":"7,786,735 "},{"v":5669961,"d":"5,669,961 "}," "]
["Options Outstanding Under 2022 Inducement Plan"," "," "," "]
["Class of Stock [Line Items]"," "," "," "]
["Common stock reserved shares for issuance",{"v":1691182,"d":"1,691,182 "},{"v":1125641,"d":"1,125,641 "}," "]
["Shares Available for Future Grant Under the 2020 Equity Incentive Plan and the 2022 Inducement Plan"," "," "," "]
["Class of Stock [Line Items]"," "," "," "]
["Common stock reserved shares for issuance",{"v":2056300,"d":"2,056,300 "},{"v":2497813,"d":"2,497,813 "}," "]
["Available for the 2020 Employee Stock Purchase Plan"," "," "," "]
["Class of Stock [Line Items]"," "," "," "]
["Common stock reserved shares for issuance",{"v":1122615,"d":"1,122,615 "},{"v":684497,"d":"684,497 "},{"v":430416,"d":"430,416 "}]
["Unvested Performance Based Restricted Stock Unit Awards Outstanding Under the 2020 Equity Incentive Plan"," "," "," "]
["Class of Stock [Line Items]"," "," "," "]
["Common stock reserved shares for issuance"," ",{"v":403000,"d":"403,000 "}," "]
["Unvested Restricted Stock Awards Outstanding Under the 2014 Stock Plan"," "," "," "]
["Class of Stock [Line Items]"," "," "," "]
["Common stock reserved shares for issuance"," ",{"v":80703,"d":"80,703 "}," "]
["Shares available for issuance related to pre-funded warrants"," "," "," "]
["Class of Stock [Line Items]"," "," "," "]
["Common stock reserved shares for issuance",{"v":11024163,"d":"11,024,163 "}," "," "]

{"sheet":"Common Stock (Additional Inform","index":44,"n_rows":11,"n_cols":4,"rows_kept":11,"merged":[[0,0,1,0]]}
["Common Stock (Additional Information) (Details) - $ / shares","12 Months Ended"]
[null,"Dec. 31, 2024","Nov. 29, 2024","Sep. 05, 2023"]
["Private Placement [Member]"," "," "," "]
["Class of Stock [Line Items]"," "," "," "]
["Share Price",{"v":9.07998,"d":"$ 9.07998"},{"v":9.08,"d":"$ 9.08"},{"v":9.84,"d":"$ 9.84"}]
["Prefunded Warrants [Member]"," "," "," "]
["Class of Stock [Line Items]"," "," "," "]
["Number of warrants",{"v":7604163,"d":"7,604,163 "}," "," "]
["Exercise price of warrant",{"v":0.0001,"d":"$ 0.0001"},{"v":0.0001,"d":"$ 0.0001"}," "]
["Exchange Of Common Stock Shares",{"v":3420000,"d":"3,420,000 "}," "," "]
["Common Stock Investor",{"v":3420000,"d":"3,420,000 "}," "," "]

{"sheet":"Stock-Based Compensation - Addi","index":45,"n_rows":19,"n_cols":5,"rows_kept":19,"merged":[[0,0,1,0],[0,1,0,3]]}
["Stock-Based Compensation - Additional Information (Details) - shares","12 Months Ended"]
[null,"Dec. 31, 2024","Dec. 31, 2023","Dec. 31, 2020","Dec. 31, 2022"]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "," "," "]
["Percent of common stock at fair market value to be exercised",{"v":1,"d":"100%"}," "," "," "]
["Number of shares vested",{"v":2213715,"d":"2,213,715 "},{"v":2329483,"d":"2,329,483 "}," "," "]
["Expiration period (in years)","10 years"," "," "," "]
["Common stock reserved shares for issuance",{"v":25556135,"d":"25,556,135 "},{"v":12336755,"d":"12,336,755 "}," "," "]
["2020 Plan"," "," "," "," "]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "," "," "]
["New shares authorized"," "," ",{"v":2152080,"d":"2,152,080 "}," "]
["Period of increase in common stock reserved for issuance"," "," ","10 years"," "]
["Percentage of increase in common stock reserved for issuance"," "," ",{"v":0.05,"d":"5%"}," "]
["2020 Plan | Maximum"," "," "," "," "]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "," "," "]
["Number of shares authorized"," "," ",{"v":6494510,"d":"6,494,510 "}," "]
["Shares available from prior equity incentive plan"," "," ",{"v":4342430,"d":"4,342,430 "}," "]
["2022 Inducement Plan"," "," "," "," "]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "," "," "]
["Common stock reserved shares for issuance"," "," "," ",{"v":2000000,"d":"2,000,000 "}]

{"sheet":"Stock-Based Compensation - Sche","index":46,"n_rows":7,"n_cols":3,"rows_kept":7,"merged":[[0,0,1,0],[0,1,0,2]]}
["Stock-Based Compensation - Schedule of Fair Value Assumptions (Details)","12 Months Ended"]
[null,"Dec. 31, 2024","Dec. 31, 2023"]
["Share-Based Payment Arrangement [Abstract]"," "," "]
["Risk-free interest rate",{"v":0.0391,"d":"3.91%"},{"v":0.0364,"d":"3.64%"}]
["Expected term (in years)","6 years 10 days","6 years 7 days"]
["Expected volatility",{"v":0.85,"d":"85%"},{"v":0.8635,"d":"86.35%"}]
["Expected dividend yield",{"v":0,"d":"0%"}," "]

{"sheet":"Stock-Based Compensation - Sc_2","index":47,"n_rows":32,"n_cols":3,"rows_kept":32,"merged":[[0,0,1,0],[0,1,0,2]]}
["Stock-Based Compensation - Schedule of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands","12 Months Ended"]
[null,"Dec. 31, 2024","Dec. 31, 2023"]
["Number of shares"," "," "]
["Outstanding as at beginning of period (in shares)",{"v":8670742,"d":"8,670,742 "}," "]
["Granted (in shares)",{"v":3478850,"d":"3,478,850 "}," "]
["Exercised (in shares)",{"v":-460744,"d":"(460,744)"}," "]
["Forfeited (in shares)",{"v":-335791,"d":"(335,791)"}," "]
["Outstanding as at end of period (in shares)",{"v":11353057,"d":"11,353,057 "},{"v":8670742,"d":"8,670,742 "}]
["Options vested and exercisable as at end of period (in shares)",{"v":6376793,"d":"6,376,793 "}," "]
["Options expected to vest as at end of period (in shares)",{"v":4976264,"d":"4,976,264 "}," "]
["Weighted Average Exercise Price"," "," "]
["Outstanding as at beginning of period (in dollars per share)",{"v":8.52,"d":"$ 8.52"}," "]
["Granted (in dollars per share)",14.21," "]
["Exercised (in dollars per share)",4.09," "]
["Forfeited (in dollars per share)",14.17," "]
["Outstanding at end of period (in dollars per share)",10.28,{"v":8.52,"d":"$ 8.52"}]
["Options vested and exercisable as at end of period (in dollars per share)",9.41," "]
["Options expected to vest as at end of period (in dollars per share)",{"v":11.4,"d":"$ 11.4"}," "]
["Weighted Average Remaining Contractual Life"," "," "]
["Weighted average remaining contractual life of outstanding options (in years)","6 years 4 months 13 days","7 years 7 months 6 days"]
["Weighted Average Remaining Contractual Life of vested and exercisable options (in years)","5 years 18 days"," "]
["Weighted Average Remaining Contractual Life of expected to vest options (in years)","8 years 18 days"," "]
["Intrinsic value of outstanding options",{"v":7519,"d":"$ 7,519"},{"v":61749,"d":"$ 61,749"}]
["Intrinsic Value of vested and exercisable options",{"v":5958,"d":"5,958 "}," "]
["Intrinsic Value of expected to vest options",{"v":1561,"d":"$ 1,561"}," "]
["Weighted-average grant date fair value of options granted (in dollars per share)",{"v":10.4,"d":"$ 10.4"},{"v":4.37,"d":"$ 4.37"}]
["Number of shares vested",{"v":2213715,"d":"2,213,715 "},{"v":2329483,"d":"2,329,483 "}]
["Weighted-average grant date fair value of options vested (in dollars per share)",{"v":6.58,"d":"$ 6.58"},{"v":6.97,"d":"$ 6.97"}]
["Fair value of options vested",{"v":14600,"d":"$ 14,600"},{"v":16200,"d":"$ 16,200"}]
["Aggregate intrinsic value of options exercised",{"v":3300,"d":"3,300 "},{"v":3500,"d":"$ 3,500"}]
["Unrecognized stock-based compensation cost",{"v":34500,"d":"$ 34,500"}," "]
["Period over which cost is expected to be recognized (in years)","2 years 7 months 9 days"," "]

{"sheet":"Stock-Based Compensation - Summ","index":48,"n_rows":29,"n_cols":3,"rows_kept":29,"merged":[[0,0,1,0],[0,1,0,2]]}
["Stock-Based Compensation - Summary of Restricted Stock Awards and Performance-Based Restricted Stock Unit Awards Activity (Details) - USD ($)","12 Months Ended"]
[null,"Dec. 31, 2024","Dec. 31, 2023"]
["Grant Date Fair Value"," "," "]
["Stock-based compensation expense",{"v":22582000,"d":"$ 22,582,000"},{"v":17256000,"d":"$ 17,256,000"}]
["Weighted average recognition period of RSA","2 years 7 months 9 days"," "]
["Unvested restricted common stock"," "," "]
["Number of Shares"," "," "]
["Unvested restricted stock and performance-based restricted stock as at beginning of period (in shares)",{"v":92659,"d":"92,659 "}," "]
["Vested (in shares)",{"v":-92659,"d":"(92,659)"}," "]
["Unvested restricted stock as at end of period (in shares)",{"v":0,"d":"0 "},{"v":92659,"d":"92,659 "}]
["Grant Date Fair Value"," "," "]
["Unvested restricted stock as at beginning of period (in dollars per share)",{"v":2.4,"d":"$ 2.4"}," "]
["Vested (in dollars per share)",2.4," "]
["Unvested restricted stock as at ending of period (in dollars per share)",{"v":0,"d":"$ 0"},{"v":2.4,"d":"$ 2.4"}]
["Grant date fair value of the RSAs vested",{"v":200000,"d":"$ 200,000"}," "]
["Stock-based compensation expense",{"v":200000,"d":"200,000 "}," "]
["Unrecognized compensation expense related to RSA",{"v":0,"d":"$ 0"}," "]
["Unvested performance-based restricted stock units"," "," "]
["Number of Shares"," "," "]
["Unvested restricted stock and performance-based restricted stock as at beginning of period (in shares)",{"v":403000,"d":"403,000 "}," "]
["Vested (in shares)",{"v":-403000,"d":"(403,000)"}," "]
["Forfeited (Shares)",{"v":0,"d":"0 "}," "]
["Unvested restricted stock as at end of period (in shares)",{"v":0,"d":"0 "},{"v":403000,"d":"403,000 "}]
["Grant Date Fair Value"," "," "]
["Unvested restricted stock as at beginning of period (in dollars per share)",{"v":3.38,"d":"$ 3.38"}," "]
["Vested (in dollars per share)",3.38," "]
["Forfeited (in dollars per share)",{"v":0,"d":"0 "}," "]
["Unvested restricted stock as at ending of period (in dollars per share)",{"v":0,"d":"$ 0"},{"v":3.38,"d":"$ 3.38"}]
["Stock-based compensation expense",{"v":1400000,"d":"$ 1,400,000"},{"v":700000,"d":"$ 700,000"}]

{"sheet":"Stock Based Compensation - Perf","index":49,"n_rows":17,"n_cols":5,"rows_kept":17,"merged":[[0,0,1,0],[0,1,0,2],[0,3,0,4]]}
["Stock Based Compensation - Performance-Based Restricted Stock Unit Awards - Additional Information (Details) - USD ($) $ in Thousands","1 Months Ended",null,"12 Months Ended"]
[null,"Jun. 30, 2024","Nov. 30, 2022","Dec. 31, 2024","Dec. 31, 2023"]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "," "," "]
["Stock-based compensation expense"," "," ",{"v":22582,"d":"$ 22,582"},{"v":17256,"d":"$ 17,256"}]
["Unvested performance-based restricted stock units"," "," "," "," "]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "," "," "]
["Vesting Percentage"," "," ",{"v":0.65,"d":"65%"},{"v":0.35,"d":"35%"}]
["Stock-based compensation expense"," "," ",{"v":1400,"d":"$ 1,400"},{"v":700,"d":"$ 700"}]
["Unvested performance-based restricted stock units | 2020 Plan | Share-based Payment Arrangement, Employee"," "," "," "," "]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "," "," "]
["Granted (in shares)"," ",{"v":710000,"d":"710,000 "}," "," "]
["Unvested performance-based restricted stock units | 2020 Plan | Share-based Payment Arrangement, Employee | Share-Based Payment Arrangement, Tranche One"," "," "," "," "]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "," "," "]
["Vesting Percentage",{"v":0.65,"d":"65%"},{"v":0.65,"d":"65%"}," "," "]
["Unvested performance-based restricted stock units | 2020 Plan | Share-based Payment Arrangement, Employee | Share-Based Payment Arrangement, Tranche Two"," "," "," "," "]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "," "," "]
["Vesting Percentage"," ",{"v":0.35,"d":"35%"}," ",{"v":0.35,"d":"35%"}]

{"sheet":"Stock-Based Compensation - 2020","index":50,"n_rows":18,"n_cols":4,"rows_kept":18,"merged":[[0,0,1,0],[0,1,0,3]]}
["Stock-Based Compensation - 2020 Employee Stock Purchase Plan - Additional Information (Details) - USD ($) $ in Thousands","12 Months Ended"]
[null,"Dec. 31, 2024","Dec. 31, 2023","Dec. 31, 2020"]
["Stock-Based Compensation"," "," "," "]
["Percent of common stock at fair market value to be exercised",{"v":1,"d":"100%"}," "," "]
["Common stock reserved shares for issuance",{"v":25556135,"d":"25,556,135 "},{"v":12336755,"d":"12,336,755 "}," "]
["Stock-based compensation expense",{"v":22582,"d":"$ 22,582"},{"v":17256,"d":"$ 17,256"}," "]
["ESPP 2020 Plan"," "," "," "]
["Stock-Based Compensation"," "," "," "]
["Percentage of eligible earnings withheld"," "," ",{"v":0.15,"d":"15%"}]
["Percent of common stock at fair market value to be exercised"," "," ",{"v":0.85,"d":"85%"}]
["Common stock reserved shares for issuance",{"v":1122615,"d":"1,122,615 "},{"v":684497,"d":"684,497 "},{"v":430416,"d":"430,416 "}]
["Period of increase in common stock reserved for issuance"," "," ","10 years"]
["Common stock outstanding percentage"," "," ",{"v":0.01,"d":"1%"}]
["Shares of common stock"," "," ",{"v":860832,"d":"860,832 "}]
["Stock-based compensation expense",{"v":600,"d":"$ 600"},{"v":500,"d":"$ 500"}," "]
["ESPP 2020 Plan | Maximum"," "," "," "]
["Stock-Based Compensation"," "," "," "]
["Offering period"," "," ","27 months"]

{"sheet":"Stock-Based Compensation - Sc_3","index":51,"n_rows":10,"n_cols":3,"rows_kept":10,"merged":[[0,0,1,0],[0,1,0,2]]}
["Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands","12 Months Ended"]
[null,"Dec. 31, 2024","Dec. 31, 2023"]
["Stock-based compensation expense"," "," "]
["Total stock-based compensation expense",{"v":22582,"d":"$ 22,582"},{"v":17256,"d":"$ 17,256"}]
["Research and development"," "," "]
["Stock-based compensation expense"," "," "]
["Total stock-based compensation expense",{"v":16543,"d":"16,543 "},{"v":11769,"d":"11,769 "}]
["General and administrative"," "," "]
["Stock-based compensation expense"," "," "]
["Total stock-based compensation expense",{"v":6039,"d":"$ 6,039"},{"v":5487,"d":"$ 5,487"}]

{"sheet":"Income Taxes - Schedule of Reco","index":52,"n_rows":13,"n_cols":3,"rows_kept":13,"merged":[[0,0,1,0],[0,1,0,2]]}
["Income Taxes - Schedule of Reconciliation of Federal Statutory Income Tax (Provision) Benefit to Effective Income Tax Provision (Details) - USD ($) $ in Thousands","12 Months Ended"]
[null,"Dec. 31, 2024","Dec. 31, 2023"]
["Reconciliation of the Federal statutory income tax provision"," "," "]
["Federal statutory income tax",{"v":27309,"d":"$ 27,309"},{"v":20060,"d":"$ 20,060"}]
["State income taxes, net of federal tax benefit",{"v":8550,"d":"8,550 "},{"v":6133,"d":"6,133 "}]
["Foreign research and development tax credit",{"v":2210,"d":"2,210 "},{"v":1411,"d":"1,411 "}]
["Permanent differences in non-tax-deductible executive compensation",{"v":-3348,"d":"(3,348)"},{"v":-2842,"d":"(2,842)"}]
["Permanent differences in foreign jurisdiction",{"v":-1650,"d":"(1,650)"},{"v":-1013,"d":"(1,013)"}]
["Permanent differences others",{"v":-469,"d":"(469)"},{"v":323,"d":"323 "}]
["Other deferred items",{"v":351,"d":"351 "},{"v":750,"d":"750 "}]
["Rate changes",{"v":-90,"d":"(90)"},{"v":-63,"d":"(63)"}]
["Valuation allowance",{"v":-32865,"d":"(32,865)"},{"v":-24761,"d":"(24,761)"}]
["Net expense for income taxes",{"v":-2,"d":"$ (2)"},{"v":-2,"d":"$ (2)"}]

{"sheet":"Income Taxes - Schedule of Defe","index":53,"n_rows":13,"n_cols":4,"rows_kept":13}
["Income Taxes - Schedule of Deferred Income Tax Assets and Liabilities (Details) - USD ($) $ in Thousands","Dec. 31, 2024","Dec. 31, 2023","Dec. 31, 2022"]
["Deferred tax assets:"," "," "," "]
["Net operating loss carryforwards",{"v":60600,"d":"$ 60,600"},{"v":44705,"d":"$ 44,705"}," "]
["Capitalized research and development",{"v":35639,"d":"35,639 "},{"v":20562,"d":"20,562 "}," "]
["Equity compensation",{"v":6963,"d":"6,963 "},{"v":5105,"d":"5,105 "}," "]
["Lease Liability",{"v":405,"d":"405 "},{"v":682,"d":"682 "}," "]
["Other",{"v":1482,"d":"1,482 "},{"v":1452,"d":"1,452 "}," "]
["Total deferred tax assets",{"v":105089,"d":"105,089 "},{"v":72506,"d":"72,506 "}," "]
["Deferred tax liabilities:"," "," "," "]
["Fixed assets",{"v":-215,"d":"(215)"},{"v":-281,"d":"(281)"}," "]
["Right-of-use assets",{"v":-372,"d":"(372)"},{"v":-646,"d":"(646)"}," "]
["Total deferred tax liabilities",{"v":-587,"d":"(587)"},{"v":-927,"d":"(927)"}," "]
["Valuation allowance",{"v":-104502,"d":"$ (104,502)"},{"v":-71579,"d":"$ (71,579)"},{"v":-47427,"d":"$ (47,427)"}]

{"sheet":"Income Taxes - Additional Infor","index":54,"n_rows":16,"n_cols":4,"rows_kept":16,"merged":[[0,0,1,0],[0,1,0,2]]}
["Income Taxes - Additional Information (Details) - USD ($) $ in Thousands","12 Months Ended"]
[null,"Dec. 31, 2024","Dec. 31, 2023","Dec. 31, 2022"]
["Operating Loss Carryforwards [Line Items]"," "," "," "]
["Valuation allowance",{"v":104502,"d":"$ 104,502"},{"v":71579,"d":"$ 71,579"},{"v":47427,"d":"$ 47,427"}]
["Change in valuation allowance",{"v":32923,"d":"$ 32,923"},{"v":24152,"d":"24,152 "}," "]
["Tax carry forward term","20 years"," "," "]
["Domestic Tax Jurisdiction [Member]"," "," "," "]
["Operating Loss Carryforwards [Line Items]"," "," "," "]
["Percentage of federal net operating loss",{"v":0.8,"d":"80%"}," "," "]
["Net operating losses",{"v":190200,"d":"$ 190,200"},{"v":150800,"d":"150,800 "}," "]
["Net operating loss carryforwards subject to expiration",{"v":3300,"d":"3,300 "}," "," "]
["Net operating loss carryforwards not subject to expiration",{"v":186900,"d":"186,900 "}," "," "]
["State and Local Jurisdiction [Member]"," "," "," "]
["Operating Loss Carryforwards [Line Items]"," "," "," "]
["Net operating losses",{"v":296700,"d":"296,700 "},{"v":187000,"d":"$ 187,000"}," "]
["Net operating loss carryforwards subject to expiration",{"v":296700,"d":"$ 296,700"}," "," "]

{"sheet":"Income Taxes - Schedule of Valu","index":55,"n_rows":6,"n_cols":3,"rows_kept":6,"merged":[[0,0,1,0],[0,1,0,2]]}
["Income Taxes - Schedule of Valuation Allowance (Details) - USD ($) $ in Thousands","12 Months Ended"]
[null,"Dec. 31, 2024","Dec. 31, 2023"]
["Income Tax Disclosure [Abstract]"," "," "]
["Valuation allowance at beginning of year",{"v":71579,"d":"$ 71,579"},{"v":47427,"d":"$ 47,427"}]
["Increase recorded to provision for income taxes",{"v":32923,"d":"32,923 "},{"v":24152,"d":"24,152 "}]
["Valuation allowance at end of year",{"v":104502,"d":"$ 104,502"},{"v":71579,"d":"$ 71,579"}]

{"sheet":"Net Loss Per Common Share - Sch","index":56,"n_rows":9,"n_cols":3,"rows_kept":9,"merged":[[0,0,1,0],[0,1,0,2]]}
["Net Loss Per Common Share - Schedule of Basic and Diluted Net Loss Per Common Share (Details) - USD ($) $ / shares in Units, $ in Thousands","12 Months Ended"]
[null,"Dec. 31, 2024","Dec. 31, 2023"]
["Numerator:"," "," "]
["Net loss",{"v":-129474,"d":"$ (129,474)"},{"v":-96655,"d":"$ (96,655)"}]
["Denominator:"," "," "]
["Weighted average shares used to compute net loss per share, basic",{"v":58743522,"d":"58,743,522 "},{"v":45247098,"d":"45,247,098 "}]
["Weighted average shares used to compute net loss per share, diluted",{"v":58743522,"d":"58,743,522 "},{"v":45247098,"d":"45,247,098 "}]
["Net loss per share, basic",{"v":-2.2,"d":"$ (2.2)"},{"v":-2.14,"d":"$ (2.14)"}]
["Net loss per share, diluted",{"v":-2.2,"d":"$ (2.2)"},{"v":-2.14,"d":"$ (2.14)"}]

{"sheet":"Net Loss Per Common Share - S_2","index":57,"n_rows":16,"n_cols":3,"rows_kept":16,"merged":[[0,0,1,0],[0,1,0,2]]}
["Net Loss Per Common Share - Schedule of Anti-dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares","12 Months Ended"]
[null,"Dec. 31, 2024","Dec. 31, 2023"]
["Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"," "," "]
["Anti-dilutive securities",{"v":11353057,"d":"11,353,057 "},{"v":9168433,"d":"9,168,433 "}]
["Employee Stock Option [Member]"," "," "]
["Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"," "," "]
["Anti-dilutive securities",{"v":11353057,"d":"11,353,057 "},{"v":8670742,"d":"8,670,742 "}]
["Performance Shares [Member]"," "," "]
["Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"," "," "]
["Anti-dilutive securities",{"v":0,"d":"0 "},{"v":403000,"d":"403,000 "}]
["Restricted Stock [Member]"," "," "]
["Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"," "," "]
["Anti-dilutive securities",{"v":0,"d":"0 "},{"v":80703,"d":"80,703 "}]
["Employee Stock [Member]"," "," "]
["Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"," "," "]
["Anti-dilutive securities",{"v":0,"d":"0 "},{"v":13988,"d":"13,988 "}]

{"sheet":"Lease - Additional Information ","index":58,"n_rows":25,"n_cols":6,"rows_kept":25}
["Lease - Additional Information (Details) $ in Thousands","Dec. 31, 2024 USD ($)","Dec. 31, 2023 USD ($)","Aug. 23, 2023 USD ($) ft²","Aug. 17, 2023 USD ($) ft²","Dec. 15, 2020 USD ($) ft²"]
["Lease"," "," "," "," "," "]
["Operating lease right-of-use assets",{"v":1314,"d":"$ 1,314"},{"v":2291,"d":"$ 2,291"}," "," "," "]
["Lease liabilities",{"v":1429,"d":"$ 1,429"}," "," "," "," "]
["Tennieh LLC"," "," "," "," "," "]
["Lease"," "," "," "," "," "]
["Area of property | ft²"," "," "," "," ",{"v":9800,"d":"9,800 "}]
["Term of contract"," "," "," "," ","5 years"]
["Security deposit"," "," "," "," ",{"v":400,"d":"$ 400"}]
["Dropbox, Inc."," "," "," "," "," "]
["Lease"," "," "," "," "," "]
["Area of property | ft²"," "," "," ",{"v":6713,"d":"6,713 "}," "]
["Term of contract"," "," "," ","2 years"," "]
["Security deposit"," "," "," ",{"v":100,"d":"$ 100"}," "]
["Operating lease right-of-use assets"," "," "," ",{"v":200,"d":"200 "}," "]
["Lease liabilities"," "," "," ",{"v":200,"d":"$ 200"}," "]
["Cambridge Redevelopment Authority"," "," "," "," "," "]
["Lease"," "," "," "," "," "]
["Area of property | ft²"," "," ",{"v":4020,"d":"4,020 "}," "," "]
["Term of contract"," "," ","3 years"," "," "]
["Operating lease right-of-use assets"," "," ",{"v":700,"d":"$ 700"}," "," "]
["Lease liabilities"," "," ",{"v":700,"d":"700 "}," "," "]
["Cambridge Redevelopment Authority | Minimum"," "," "," "," "," "]
["Lease"," "," "," "," "," "]
["Security deposit"," "," ",{"v":100,"d":"$ 100"}," "," "]

{"sheet":"Lease - Summary of Total Lease ","index":59,"n_rows":7,"n_cols":3,"rows_kept":7,"merged":[[0,0,1,0],[0,1,0,2]]}
["Lease - Summary of Total Lease Expense (Details) - USD ($) $ in Thousands","12 Months Ended"]
[null,"Dec. 31, 2024","Dec. 31, 2023"]
["Lease expense"," "," "]
["Straight-line operating lease expense",{"v":1150,"d":"$ 1,150"},{"v":1297,"d":"$ 1,297"}]
["Short-term lease expense"," ",{"v":164,"d":"164 "}]
["Variable lease expense",{"v":382,"d":"382 "},{"v":140,"d":"140 "}]
["Total operating lease expense",{"v":1532,"d":"$ 1,532"},{"v":1601,"d":"$ 1,601"}]

{"sheet":"Lease - Summary of Supplemental","index":60,"n_rows":5,"n_cols":3,"rows_kept":5,"merged":[[0,0,1,0],[0,1,0,2]]}
["Lease - Summary of Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands","12 Months Ended"]
[null,"Dec. 31, 2024","Dec. 31, 2023"]
["Leases [Abstract]"," "," "]
["Operating cash flows from operating leases",{"v":1162,"d":"$ 1,162"},{"v":1231,"d":"$ 1,231"}]
["Supplemental noncash information on lease liability arising from obtaining a right-use-asset"," ",{"v":896,"d":"$ 896"}]

{"sheet":"Lease - Summary of Future Minim","index":61,"n_rows":9,"n_cols":3,"rows_kept":9}
["Lease - Summary of Future Minimum Lease Payments (Details) - USD ($) $ in Thousands","Dec. 31, 2024","Dec. 31, 2023"]
["Future minimum lease payments"," "," "]
["2025",{"v":1245,"d":"$ 1,245"}," "]
["2026",{"v":263,"d":"263 "}," "]
["Total future minimum lease payments",{"v":1508,"d":"1,508 "}," "]
["Less: Interest",{"v":-79,"d":"(79)"}," "]
["Total lease liabilities at present value",{"v":1429,"d":"1,429 "}," "]
["Lease liabilities, current",{"v":1172,"d":"1,172 "},{"v":988,"d":"$ 988"}]
["Lease liabilities, non-current",{"v":257,"d":"$ 257"},{"v":1429,"d":"$ 1,429"}]

{"sheet":"Lease - Summary of Lease Term a","index":62,"n_rows":4,"n_cols":3,"rows_kept":4}
["Lease - Summary of Lease Term and Discount Rate (Details)","Dec. 31, 2024","Dec. 31, 2023"]
["Leases [Abstract]"," "," "]
["Weighted-average remaining lease term (years)","1 year 3 months 7 days","2 years 3 months"]
["Weighted-average discount rate",{"v":0.09,"d":"9%"},{"v":0.09,"d":"9%"}]

{"sheet":"Commitments and Contingencies -","index":63,"n_rows":44,"n_cols":7,"rows_kept":44,"merged":[[0,0,1,0],[0,5,0,6]]}
["Commitments and Contingencies - Additional Information (Details) $ in Thousands",{"$nulls":3},"1 Months Ended","12 Months Ended"]
[null,"Nov. 29, 2024 USD ($)","Jun. 28, 2024 USD ($)","Sep. 05, 2023 USD ($)","Jun. 30, 2022 USD ($)","Dec. 31, 2024 USD ($) Item","Dec. 31, 2023 USD ($)"]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "]
["Reimbursable research and development costs from a collaboration partner"," "," "," "," ",{"v":0,"d":"$ 0"},{"v":1491,"d":"$ 1,491"}]
["Research and development"," "," "," "," ",{"v":124517,"d":"124,517 "},{"v":86140,"d":"86,140 "}]
["Senior Secured Loan Facility"," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "]
["Term of loan agreement"," "," ","4 years"," "," "," "]
["Aggregate principal amount"," "," ",{"v":50000,"d":"$ 50,000"}," "," "," "]
["Amount available for draw down, Private placement."," "," ",{"v":25000,"d":"25,000 "}," "," "," "]
["Amount available for draw down, Lenders discretion"," "," ",{"v":25000,"d":"$ 25,000"}," ",{"v":25000,"d":"$ 25,000"}," "]
["Maturity date"," "," ","Aug.  01,  2027"," "," "," "]
["Interest rate"," "," ",{"v":0.08,"d":"8%"}," "," "," "]
["Incremental interest rate at the event of default"," "," ",{"v":0.03,"d":"3%"}," "," "," "]
["Unused commitment fee percentage"," "," ",{"v":0.015,"d":"1.50%"}," "," "," "]
["Amendment of Original Loan Agreement"," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "]
["Aggregate principal amount"," ",{"v":100000,"d":"$ 100,000"}," "," "," "," "]
["Amount currently available for draw down"," ",{"v":25000,"d":"25,000 "}," "," "," "," "]
["Amount available for draw down upon achieving certain milestones related to execution of first line pivotal phase 3"," ",{"v":25000,"d":"25,000 "}," "," "," "," "]
["Amount available for draw down, Lenders discretion"," ",{"v":50000,"d":"$ 50,000"}," "," "," "," "]
["Maturity date"," ","Jul.  01,  2028"," "," "," "," "]
["Novartis Pharma Agreement"," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "]
["Exclusive negotiation period after receipt of written notice","30 days"," "," "," "," "," "]
["Exclusive negotiation period maximum","120 days"," "," "," "," "," "]
["Proposed sale negotiation period","45 days"," "," "," "," "," "]
["Aggregate amount of units actually supplied",{"v":275000,"d":"$ 275,000"}," "," "," "," "," "]
["Novartis Pharma Agreement | Bio Medical Research Inc"," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "]
["Number of patients | Item"," "," "," "," ",{"v":60,"d":"60 "}," "]
["Costs reimbursable from Novartis"," "," "," "," ",{"v":0,"d":"$ 0"},{"v":2000,"d":"2,000 "}]
["Reimbursable research and development costs from a collaboration partner"," "," "," "," "," ",{"v":1500,"d":"$ 1,500"}]
["Aurigene Agreement"," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "]
["Milestone payments to be paid to collaborative partner"," "," "," ",{"v":60000,"d":"$ 60,000"}," "," "]
["Upfront payment, research and development."," "," "," ",{"v":8000,"d":"8,000 "}," "," "]
["Research and development"," "," "," "," ",{"v":0,"d":"0 "}," "]
["Aurigene Agreement | Clinical Cevelopment and Regulatory Milestones"," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "]
["Research and development"," "," "," "," ",{"v":5000,"d":"$ 5,000"}," "]
["Aurigene Agreement | Commercial Milestone"," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "]
["Milestone payments to be paid to collaborative partner"," "," "," ",{"v":370000,"d":"$ 370,000"}," "," "]